<SEC-DOCUMENT>0001829126-26-001911.txt : 20260304
<SEC-HEADER>0001829126-26-001911.hdr.sgml : 20260304
<ACCEPTANCE-DATETIME>20260304091652
ACCESSION NUMBER:		0001829126-26-001911
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260303
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20260304
DATE AS OF CHANGE:		20260304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KALA BIO, Inc.
		CENTRAL INDEX KEY:			0001479419
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				270604595
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38150
		FILM NUMBER:		26719062

	BUSINESS ADDRESS:	
		STREET 1:		1167 MASSACHUSETTS AVENUE
		CITY:			ARLINGTON
		STATE:			MA
		ZIP:			02476
		BUSINESS PHONE:		781-996-5252

	MAIL ADDRESS:	
		STREET 1:		1167 MASSACHUSETTS AVENUE
		CITY:			ARLINGTON
		STATE:			MA
		ZIP:			02476

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Kala Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20091223
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kalabio_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:kala="http://kala/20260303">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_kala_kala_20260303 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20260303_20260303 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001479419 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000004" name="dei:EntityCentralIndexKey">0001479419</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="kala-20260303.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-03-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479419</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-03-03</xbrli:startDate>
        <xbrli:endDate>2026-03-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>FORM
<span id="xdx_90E_edei--DocumentType_c20260303__20260303_ziyfI0oX1MGa"><ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d)<br/>
of the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <b><span id="xdx_90F_edei--DocumentPeriodEndDate_c20260303__20260303_zSlBQtOe27gh"><ix:nonNumeric contextRef="AsOf2026-03-03" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">March 3, 2026</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b><span id="xdx_900_edei--EntityRegistrantName_c20260303__20260303_zzSAQjzyKDJ9"><ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000011" name="dei:EntityRegistrantName">KALA BIO, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in its Charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center; text-indent: 0pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20260303__20260303_zji7zZrF27Ec"><ix:nonNumeric contextRef="AsOf2026-03-03" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center; text-indent: 0pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityFileNumber_c20260303__20260303_z6z8UZ8yqtjl"><ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000013" name="dei:EntityFileNumber">001-38150</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center; text-indent: 0pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20260303__20260303_zdPHzoLqcr2b"><ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000014" name="dei:EntityTaxIdentificationNumber">27-0604595</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or Other Jurisdiction <br/>
of Incorporation)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    <br/>
File Number)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer <br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20260303__20260303_zFj9i50Gxam2"><ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000015" name="dei:EntityAddressAddressLine1">1167 Massachusetts Avenue</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressCityOrTown_c20260303__20260303_zqg3iZ4NNAsd"><ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000016" name="dei:EntityAddressCityOrTown">Arlington</ix:nonNumeric></span>,
<span id="xdx_90A_edei--EntityAddressStateOrProvince_c20260303__20260303_ztJufPI7KPG8"><ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000017" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressPostalZipCode_c20260303__20260303_z8RVDtgRadE6"><ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000018" name="dei:EntityAddressPostalZipCode">02476</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of Principal Executive Offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <b><span id="xdx_90B_edei--CityAreaCode_c20260303__20260303_zw9MLzEY9RL5"><ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000019" name="dei:CityAreaCode">(781)</ix:nonNumeric></span> <span id="xdx_90A_edei--LocalPhoneNumber_c20260303__20260303_zYOIMUXsfzV3"><ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000020" name="dei:LocalPhoneNumber">996-5252</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Not
applicable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
Name or Former Address, if Changed Since Last Report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt; width: 0.25in"><span id="xdx_90D_edei--WrittenCommunications_c20260303__20260303_z6dACPwkseJj"><ix:nonNumeric contextRef="AsOf2026-03-03" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span id="xdx_901_edei--SolicitingMaterial_c20260303__20260303_zlLuIOjTF0Wl"><ix:nonNumeric contextRef="AsOf2026-03-03" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material
    pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span id="xdx_900_edei--PreCommencementTenderOffer_c20260303__20260303_zZGrSZuFSpwf"><ix:nonNumeric contextRef="AsOf2026-03-03" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20260303__20260303_zZF8n0TZExfd"><ix:nonNumeric contextRef="AsOf2026-03-03" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center; text-indent: 0pt; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center; text-indent: 0pt; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    symbol(s)</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center; text-indent: 0pt; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20260303__20260303_zJypvpOfHXci"><ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000025" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20260303__20260303_zF2GaxTUNg53"><ix:nonNumeric contextRef="AsOf2026-03-03" id="Fact000026" name="dei:TradingSymbol">KALA</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_903_edei--SecurityExchangeName_c20260303__20260303_zEDgsLqzQOv1"><ix:nonNumeric contextRef="AsOf2026-03-03" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_900_edei--EntityEmergingGrowthCompany_c20260303__20260303_z16AMokQPqwa"><ix:nonNumeric contextRef="AsOf2026-03-03" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 1in"><b>Item 1.01.</b></td>
    <td style="font-size: 10pt; text-align: justify"><b>Entry into a Material Definitive Agreement.</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 3, 2026 (the &#8220;Effective Date&#8221;),
KALA BIO, Inc. (the &#8220;Company&#8221;) and 2624465 Ontario Inc. o/a Younet AI, an Ontario corporation (&#8220;Younet&#8221;) entered
into a Platform Development and Exclusive License Agreement (the &#8220;Agreement&#8221;) pursuant to which the Company obtained a worldwide
exclusive license (the &#8220;Exclusive License&#8221;) of Younet&#8217;s proprietary, custom biomedical artificial intelligence research
platform (the &#8220;Researgency Platform&#8221;), together with associated trademarks and intellectual property. The term of the Agreement
is for 12 months following the Effective Date (the &#8220;Initial Term&#8221;), with the option by the Company to renew the agreement
for successive 12 months terms (each, a &#8220;Renewal Term&#8221;), in each case by providing notice to Younet pursuant to the terms
of the Agreement (the &#8220;Extension Notice&#8221;). Pursuant to the Agreement, Younet shall also provide to the Company certain deliverables
and services related to the Researgency Platform, with certain additional deliverables to be provided by Younet in the event of a Renewal
Term, in each case with all operating costs relating to the Researgency Platform to be paid by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration of the services to be performed
by Younet under the Agreement, the Company has agreed to pay to Younet for the Initial Term a cash fee of up to $530,000 consisting of
(i) $80,000 in cash, which was paid by the Company on the Effective Date, and (ii) in the event the Company delivers to Younet a written
notice electing to engage Younet for the continued development of Researgency, $450,000 in cash, payable in 9 monthly installments of
$50,000, pursuant to the terms of the Agreement. Such notice may be provided at any time on or after the first business day of the third
month following the Effective Date and such continued development may be terminated upon 30 days notice by the Company. In addition, the
Company has agreed to issue to Younet 5,000,000 shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common
Stock&#8221;), within 10 business days of the Effective Date. In addition, each time the Agreement is extended for a Renewal Term, the
Company shall (i) pay to Younet $250,000 in cash and (ii) issue to Younet 5,000,000 shares of Common Stock within 10 business days of
the Extension Notice. Any shares of Common Stock issuable to Younet pursuant to the Agreement shall herein be referred to as the &#8220;Younet
Shares.&#8221; Except for certain block trades, during the Term (as defined in the Agreement) and for the twelve months thereafter, Younet
shall not sell any Younet Shares on any Trading Day (as defined in the Agreement) in an amount that exceeds 3% of the Daily Trading Volume
(as defined in the Agreement) for such Trading Day.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Younet has granted to the Company
an irrevocable option, exercisable at any time during the Initial Term or any Renewal Terms, to acquire all of the issued and outstanding
equity interests of Younet, or, at the Company&#8217;s election, substantially all of the assets of Younet, for a total purchase price
of $55,000,000, subject to the terms of the Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company does not deliver an Extension Notice
prior to the expiration of the Initial Term or any Renewal Term, the Agreement shall expire automatically at the end of the applicable
term. In addition, the Agreement may be terminated by either party (i) for uncured material breach or (ii) due to the insolvency of the
other party. Upon termination or expiration, (a) the Exclusive License will terminated, (b) all licenses granted to Younet with respect
to KALA Data (as defined in the Agreement) will immediately terminate, (c) all licenses granted to the Company with respect to Younet
Background IP (as defined in the Agreement) will survive in accordance with their terms, and (d) all Work Product (as defined in the Agreement)
completed as of the date of termination shall be delivered to and owned by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The License Agreement additionally includes customary
representations and warranties, covenants, and indemnification obligations for a transaction of this nature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the terms of the
Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which is filed
as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 1in"><b>Item 3.02.</b></td>
    <td style="font-size: 10pt; text-align: justify"><b>Unregistered Sales of Equity Securities.</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The matters described in Item 1.01 of this Current
Report on Form 8-K with respect to the Younet Shares are incorporated herein by reference. In connection with the issuance of the Younet
Shares as described in Item 1.01, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Regulation D promulgated thereunder for transactions not involving a public
offering. This report shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white">
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt; width: 1in"><b>Item 7.01.</b></td>
    <td style="font-size: 10pt; text-align: justify"><b>Regulation FD Disclosure.</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 4, 2026, the Company issued a press release
announcing its entry into the Agreement and other business updates. A copy of the press release is attached hereto as Exhibit 99.1 to
this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Item 7.01 and Exhibit
99.1 shall not be deemed &#8220;filed&#8221; for purposes of the&#160;Securities Exchange Act of 1934, as amended, nor shall it be deemed
incorporated by reference in any filing under the&#160;Securities Act of 1933, as amended, except as shall be expressly set forth by
specific reference in such a filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="border-bottom: Black 1pt solid; text-align: justify"><b>Exhibit No.</b></td>
    <td style="text-align: justify; padding-bottom: 1pt"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: justify"><b>Description</b></td></tr>
                                                                                                                                          <tr style="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
<td style="width: 9%; text-align: justify">10.1</td>
    <td style="text-align: justify; width: 1%">&#160;</td><td style="text-align: justify; width: 90%"><a href="kalabio_ex10-1.htm">Platform Development and Exclusive License Agreement, dated March&#160;3, 2026.</a></td>
</tr>
<tr style="vertical-align: top; text-align: justify; background-color: White">
<td style="text-align: justify">99.1</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: justify"><a href="kalabio_ex99-1.htm">Press Release, dated March&#160;4, 2026.</a></td>
</tr>
<tr style="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
<td style="text-align: justify">104</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: justify">Cover Page Interactive Data File (embedded within the inline
XBRL document)</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>



<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>KALA
    BIO, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;4,
    2026</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Avi Minkowitz</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 50%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 4%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 5%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 41%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avi
    Minkowitz</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive
    Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVsKwkAMRVfQPYT5lr58gP20aBGrlFLE38FGGWwnJTO+luQunbaIIRCSe0+uEBOR0UY1yHBalTlU2HaNtAglXpBRn9E50u0uATdLvCpjWWo7rD8wJcegYxb+TLr74Hwog3UCYRxEyyBeQDhNZnMo9sLr9ZT0RdWorZINSF1DwdSxQiv5PX6o5Is0te8h6YhsFOkEIj8c5Q/EYRTDgR7ySXwzkOep8CZDeSJjunfOtX5Z1D0J6wZbF2dG+t/eF8+5SmM= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>kalabio_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLATFORM DEVELOPMENT AND EXCLUSIVE LICENSE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS PLATFORM DEVELOPMENT AND EXCLUSIVE LICENSE AGREEMENT</B> (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of March&#160;3, 2026 (the &ldquo;<B>Effective Date</B>&rdquo;), by and between:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KALA BIO, Inc.</B>, a Delaware corporation, with its principal office at 1167 Massachusetts Avenue, Arlington, MA 02476 (the &ldquo;<B>Company</B>&rdquo; or &ldquo;<B>KALA</B>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2624465 Ontario Inc. o/a Younet AI</B>, an Ontario corporation, with its principal office at 7191 Yonge St., Suite 812, Thornhill, Ontario L3T 0C4 (the &ldquo;<B>Developer</B>&rdquo; or &ldquo;<B>Younet</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of KALA and Younet is referred to individually as a &ldquo;<B>Party</B>&rdquo; and collectively as the &ldquo;<B>Parties</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BACKGROUND</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KALA is a clinical-stage biopharmaceutical company listed on the Nasdaq Stock Market (NASDAQ: KALA) with proprietary biological assets, including its mesenchymal stem cell secretome (MSC-S) platform and related intellectual property, and is pursuing a dual strategy combining its proprietary biologics pipeline with a scalable artificial intelligence platform-as-a-service business designed to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Younet is a specialized artificial intelligence development firm with expertise in deploying custom large language models (&ldquo;<B>LLMs</B>&rdquo;), retrieval-augmented generation (&ldquo;<B>RAG</B>&rdquo;) pipelines, and scalable AI platforms, and has developed and deployed over 100 custom AI agents for enterprise clients;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KALA desires to obtain a worldwide exclusive license of Younet&rsquo;s proprietary, custom biomedical AI research platform (&ldquo;<B>Researgency</B>&rdquo;), together with associated trademarks and IP, to enhance KALA&rsquo;s existing biologics research capabilities and accelerate insight generation from the Company&rsquo;s proprietary scientific datasets, and to establish the foundation for deploying the Platform as on-premises, data-sovereign AI infrastructure to external biotech and pharmaceutical clients on a platform-as-a-service basis;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Younet has completed a feasibility study confirming the technical viability of adapting its Researgency architecture to serve KALA&rsquo;s biomedical research and data science requirements;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Parties desire to establish the terms under which Younet will license, manage and support Researgency platform for KALA, including an exclusive license for Platform as a service for biotechnology applications, structured as an initial period with successive optional renewal terms, and the compensation to be paid to Younet in connection therewith; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KALA intends to serve as its own first deployment client during the Initial Term, applying the Platform&rsquo;s AI capabilities to the Company&rsquo;s proprietary MSC-S platform datasets, KPI-012 preclinical and clinical data, and existing intellectual property portfolio, before scaling Platform deployment to external biotech and pharmaceutical partners on a recurring subscription basis.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW, THEREFORE</B>, in consideration of the mutual covenants, agreements, representations, and warranties contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE I </B><BR><B>DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biotechnology Field</B><FONT STYLE="font-weight: normal">&rdquo; means the research, development, discovery, analysis, modeling, optimization, and commercialization of biological therapeutics, pharmaceutical compounds, drug candidates, biologics, gene therapies, cell therapies, diagnostic tools, and related biomedical applications, including but not limited to computational biology, AI-driven drug discovery, clinical trial design and analysis, biomedical literature review, regulatory analysis, and bioinformatics.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidential Information</B><FONT STYLE="font-weight: normal">&rdquo; means all non-public information disclosed by one Party to the other in connection with this Agreement, whether in written, oral, electronic, or visual form, including but not limited to trade secrets, proprietary data, biological data, clinical data, patient data (to the extent de-identified and compliant with applicable law), algorithms, source code, business plans, financial information, customer lists, and technical know-how.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Daily Volume Cap</B><FONT STYLE="font-weight: normal">&rdquo; has the meaning set forth in Section&#160;4.04(f).</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Data Sovereignty</B><FONT STYLE="font-weight: normal">&rdquo; means the principle that all data provided by or generated on behalf of a client (including KALA and any sublicensee) in connection with the Platform shall remain within such client&rsquo;s own secure infrastructure and under such client&rsquo;s exclusive custody and control at all times, and shall not be transmitted to, stored on, or accessible from any external servers, public cloud environments (provided that Younet may utilize private or isolated cloud environments solely with the prior written consent of KALA (or the applicable sublicensee), which consent shall specify the permitted cloud provider, the scope of data to be processed, and the security and isolation standards to be maintained, and which consent may be revoked upon thirty (30) days&rsquo; prior written notice), or third-party AI services without the express prior written consent of such client. </FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deliverables</B><FONT STYLE="font-weight: normal">&rdquo; means the Platform, training materials, deployment scripts, configuration files, and other work product delivered by Younet to KALA under this Agreement, as further described in the Scope of Work (Exhibit A).</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.06</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extension Fee</B><FONT STYLE="font-weight: normal">&rdquo; means the cash and equity consideration payable by KALA for each Renewal Term, as set forth in Section 4.02.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.07</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Extension Notice</b><FONT STYLE="font-weight: normal">&rdquo; means a written notice delivered by KALA to Younet electing to extend the Agreement for an additional Renewal Term, which notice shall be accompanied by the applicable Extension Fee.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.08</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><B>Initial Term</B></b><FONT STYLE="font-weight: normal">&rdquo; means the period commencing on the Effective Date and ending on the date that is twelve (12) months after the Effective Date.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.09</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
    Property</B><FONT STYLE="font-weight: normal">&rdquo; or &ldquo;</FONT><B>IP</B><FONT STYLE="font-weight: normal">&rdquo; means all
    patents, copyrights, trademarks, trade secrets, know-how, inventions, discoveries, algorithms, models, training data configurations,
    software code, and any other proprietary rights, whether or not registered.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>KALA Data</b><FONT STYLE="font-weight: normal">&rdquo; means all data, datasets, biological information, clinical records, research materials, intellectual property, and proprietary information provided by KALA to Younet for use in connection with the development, training, or deployment of the Platform.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>On-Premises Deployment</b><FONT STYLE="font-weight: normal">&rdquo; means the deployment and operation of the Platform (or any component thereof) directly within a client&rsquo;s own secure computing environment, on servers owned or controlled by such client, such that all Platform processing, data storage, and AI inference occurs locally within the client&rsquo;s infrastructure. </FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Platform</b><FONT STYLE="font-weight: normal">&rdquo; means the Researgency biomedical AI research platform, including all custom AI agents, LLM configurations, RAG pipelines, user interfaces, APIs, dashboards, and supporting infrastructure developed by Younet for KALA under this Agreement.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.13</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Renewal Term</b><FONT STYLE="font-weight: normal">&rdquo; means each successive twelve-month period for which KALA elects to extend this Agreement by delivering an Extension Notice and paying the applicable Extension Fee, as set forth in Article 4.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.14</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted
    Shares</B><FONT STYLE="font-weight: normal">&rdquo; means the shares of KALA common stock issued to Younet pursuant to Article 4,
    which shares shall be &ldquo;restricted securities&rdquo; as defined under Rule&#160;144 promulgated under the Securities Act of
    1933, as amended (the &ldquo;</FONT><B>Securities Act</B><FONT STYLE="font-weight: normal">&rdquo;).</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.15</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term</b><FONT STYLE="font-weight: normal">&rdquo; means the Initial Term together with all Renewal Terms, if any.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">1.16</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Younet Background IP</b><FONT STYLE="font-weight: normal">&rdquo; means all Intellectual Property owned or controlled by Younet prior to the Effective Date or developed by Younet independently of this Agreement, including Younet&rsquo;s core platform architecture, proprietary training algorithms, general-purpose LLM frameworks, and pre-existing software libraries.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE II </B><BR><B>SCOPE OF WORK AND DELIVERABLES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Engagement</B><FONT STYLE="font-weight: normal">.
    KALA hereby licenses from Younet, and Younet hereby grants such license for, the Platform, on the terms and conditions set forth
    herein. Younet shall provide KALA with initial access to and a working Platform during the Initial Term, as further described below.
    Full-scale configuration, customization, agent development, and ongoing deployment services shall be provided by Younet.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Initial Deliverables. </B><FONT STYLE="font-weight: normal">During the Initial Term, Younet shall deliver the following (collectively, the &ldquo;</FONT><B>Initial Deliverables</B><FONT STYLE="font-weight: normal">&rdquo;)</FONT><B>:</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access to the Researgency platform in a standalone instance which may initially be hosted within a dedicated private cloud environment and which shall be designed and architected to support transition to full On-Premises Deployment within client environments, with a web-interface accessible at www.researgency.ai or such other URL as the Parties may agree (the &ldquo;<B>Platform Access</B>&rdquo;). For the avoidance of doubt, the Platform architecture shall be designed from inception for On-Premises Deployment and Data Sovereignty, consistent with the Platform&rsquo;s intended use as on-premises AI infrastructure for the biotechnology industry;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A working Platform demonstrating its core biomedical AI capabilities, including bio-med specific LLM agents functionality and user interface, sufficient for KALA to evaluate the Platform&rsquo;s suitability for its research needs and to demonstrate the Platform&rsquo;s capabilities to prospective clients and collaborators, including but not limited to the Platform&rsquo;s on-premises deployment architecture, custom agent configuration capabilities, retrieval-augmented generation (RAG) pipeline functionality, and data sovereignty features (the &ldquo;<B>Researgency Platform</B>&rdquo;);</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Introductory platform documentation and orientation materials; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customary under Younet standards introductory training for KALA personnel on use of the Platform.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Training and deployment of custom private LLM bio-med agents for continuing launch within the platform.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ongoing platform maintenance, infrastructure support, and technical assistance.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial configuration and adaptation of the Platform for application to KALA&rsquo;s proprietary MSC-S platform datasets, KPI-012 preclinical and clinical data, and existing intellectual property portfolio, such that KALA may serve as its own first deployment client and conduct AI-driven reassessment of its historical datasets during the Initial Term.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating
    Costs</B><FONT STYLE="font-weight: normal">. For clarity, all ongoing and recurring costs required to host, operate, and maintain
    the Researgency platform for KALA, including without limitation servers, on-premises infrastructure, cloud compute, storage, networking,
    managed services, third-party subscriptions, model/API usage fees, monitoring/logging, security tooling, and any other monthly or
    usage-based charges associated with the Platform, shall be borne by Younet during the Initial Term. In the event the parties wish
    to amend the specifics of the Platform, a separate written maintenance/support agreement or change order to provide such services
    and fees on a pass-through basis shall be entered into between Younet and KALA, and Younet shall provide an estimated budget to KALA
    and those costs will be borne by KALA.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Renewal
    Term Deliverables</B><FONT STYLE="font-weight: normal">. Upon KALA&rsquo;s delivery of an Extension Notice and payment of the applicable
    Extension Fee for any Renewal Term, Younet shall, during such Renewal Term, use commercially reasonable efforts to provide the following
    services and deliverables (collectively, &ldquo;</FONT><B>Renewal Deliverables</B><FONT STYLE="font-weight: normal">&rdquo;):</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuing deployment and configuration of the Researgency platform, including secure On-Premises Deployment within each client&rsquo;s own secure computing environment (or, where agreed by the applicable client, dedicated private cloud infrastructure), user interfaces, administrative dashboards, and integration with KALA&rsquo;s existing data systems, in each case in a manner consistent with the principles of Data Sovereignty;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RAG pipeline configuration optimized for biomedical and pharmaceutical datasets, enabling the Platform to retrieve, synthesize, and analyze information from KALA&rsquo;s proprietary data, published scientific literature, and regulatory databases;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set up and configuration of custom Bio-Research agents (such number and specializations of which to be agreed in the applicable Extension Notice), to be trained and grown according to KALA&rsquo;s data specifications, with all training data to be supplied and/or paid for by KALA;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ongoing platform maintenance, infrastructure support, and technical assistance;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Costs. For clarity, during any Renewal Term, all ongoing and recurring costs required to host, operate, and maintain the Researgency platform for KALA, including without limitation servers, on-prem infrastructure, cloud compute, storage, networking, managed services, third-party subscriptions, model/API usage fees, monitoring/logging, security tooling, and any other monthly or usage-based charges associated with the Platform, shall be borne by KALA. Younet to provide estimated budget ahead of each quarter;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Updated documentation and additional training for KALA personnel as reasonably required; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such additional development, data science, or consulting services as the Parties may agree in writing, subject to additional compensation as set forth in Section 4.04.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
    Obligation to Extend</B><FONT STYLE="font-weight: normal">. For the avoidance of doubt, KALA is under no obligation to deliver an
    Extension Notice or to extend this Agreement beyond the Initial Term. KALA&rsquo;s decision whether to extend shall be in its sole
    and absolute discretion. Younet acknowledges and agrees that it shall have no claim against KALA for failing to extend, and that
    the Upfront Payment and Initial Shares (each as defined in Article 4) constitute full and complete consideration for the Initial
    Deliverables and the grant of the license during the Initial Term.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.06</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Younet&rsquo;s
    Resource Commitment</B><FONT STYLE="font-weight: normal">. For any Renewal Term, Younet shall not be required to commit dedicated
    development personnel, infrastructure resources, or material capital expenditures to the development of the Platform beyond the Initial
    Deliverables unless KALA has such request in writing, under mutually agreed upon budget. Upon receipt of an Extension Notice and
    Extension Fee, Younet shall promptly allocate the resources necessary to deliver the applicable Renewal Deliverables in accordance
    with this Agreement.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.07</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accelerated
    Extension</B><FONT STYLE="font-weight: normal">. KALA may deliver an Extension Notice and pay the applicable Extension Fee at any
    time, including prior to the expiration of the then-current Initial Term or Renewal Term. Upon receipt of an accelerated Extension
    Fee, the new Renewal Term shall commence immediately upon the later of: (a) the date of receipt of the Extension Fee; or (b) the
    expiration of the then-current term, and Younet shall promptly commence delivery of the applicable Renewal Deliverables.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.08</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Initial
    Term Timeline</B><FONT STYLE="font-weight: normal">. Younet shall use commercially reasonable efforts to deliver the Initial Deliverables
    (Kala customized Platform Access) within fourteen (14) business days of the Effective Date (the &ldquo;</FONT><B>Initial Delivery
    Date</B><FONT STYLE="font-weight: normal">&rdquo;).</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.09</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Milestones</B><FONT STYLE="font-weight: normal">.
    The Initial Deliverables shall proceed in accordance with the following schedule:</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone 1 &mdash; Platform Access: Standalone cloud Researgency instance provisioned and web- interface accessible at www.researgency.ai (Days 1&ndash;5); and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone 2 &mdash; Platform Delivery: Working Platform with bio-med specific LLM agent functionality delivered for KALA evaluation (Days 5&ndash;14).</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestones for Renewal Term Deliverables shall be set forth in the applicable Extension Notice or a mutually agreed development plan for each Renewal Term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acceptance</B><FONT STYLE="font-weight: normal">.
    Upon delivery of each Milestone, KALA shall have fifteen (15) business days to review and either accept the deliverables or provide
    written notice of deficiencies (each, a &ldquo;</FONT><B>Deficiency Notice</B><FONT STYLE="font-weight: normal">&rdquo;). Younet
    shall use commercially reasonable efforts to cure any identified deficiencies within fifteen (15) business days of receiving such
    notice and shall re-deliver the applicable Milestone deliverables to KALA for further review.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Upon re-delivery, KALA shall have an additional ten (10) business days to review and either accept or provide a further Deficiency Notice. If, after two (2) rounds of cure and re-delivery, material deficiencies remain unresolved, either Party may escalate the matter for resolution by the Parties&rsquo; respective senior executives. If such senior executives are unable to resolve the dispute within fifteen (15) business days of escalation, the matter shall be resolved in accordance with Section 11.04 (Dispute Resolution). For the avoidance of doubt, no deliverable shall be deemed accepted without KALA&rsquo;s express written acceptance or, in the absence of a Deficiency Notice, upon the expiration of the applicable review period following the final re-delivery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Change
    Orders</B><FONT STYLE="font-weight: normal">. Any changes to the Scope of Work, timeline, or Deliverables after the Effective Date
    shall require a written change order signed by authorized representatives of both Parties, specifying the nature of the change, any
    impact on the timeline, and any additional compensation.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform
    Design Principles</B><FONT STYLE="font-weight: normal">. The Parties acknowledge and agree that the Platform shall be designed, developed,
    and deployed in accordance with the following core principles:</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>On-Premises Architecture</B>. The Platform architecture shall be designed from inception for On-Premises Deployment, enabling the Platform to be deployed directly within each client&rsquo;s own secure environment, on such client&rsquo;s own servers, under such client&rsquo;s own control. In this model, KALA (or its sublicensee, as applicable) provides the AI platform, the purpose-built biomedical agents, and the ongoing optimization, while the client retains full ownership and custody of their data at all times.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Data Sovereignty</B>. Subject to Section&#160;5.06, the Platform shall be configured and operated such that no proprietary information, biological data, trade secrets, clinical datasets, or other confidential client data is transmitted to, stored on, or processed by any external servers, public cloud environments, or third-party AI services, unless the applicable client has provided express prior written consent. Each client&rsquo;s data shall remain entirely within such client&rsquo;s own infrastructure at all times.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Multi-Client Scalability</B>. The Platform architecture shall be designed from inception for multi-client deployment, enabling KALA to onboard additional biotech and pharmaceutical clients through sublicenses without requiring material rebuilding of core Platform systems.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Custom Agent Configuration</B>. The Platform shall support the deployment of purpose-built AI agents configured specifically for each client&rsquo;s therapeutic focus areas, data types, and research objectives, rather than generic, multi-purpose models.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phased
    Deployment Strategy</B><FONT STYLE="font-weight: normal">. The Parties acknowledge that KALA intends to deploy the Platform in a
    phased approach, as follows:</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase 1 &mdash; Internal Validation</B>. During the Initial Term, KALA shall serve as its own first deployment client, applying the Platform&rsquo;s AI capabilities to the Company&rsquo;s proprietary MSC-S platform datasets, KPI-012 preclinical and clinical data, and existing intellectual property portfolio. KALA expects to use the Platform during the Initial Term to (i) reassess historical preclinical and clinical datasets, (ii) identify additional therapeutic indications or development pathways, (iii) support trial design optimization and probability-of-success modeling, (iv) evaluate regulatory and commercialization strategies, and (v) automate literature review and competitive intelligence functions.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase 2 &mdash; External Deployment</B>. Following successful internal validation, KALA intends to begin sublicensing the Platform to external biotech and pharmaceutical clients on a recurring subscription basis, in accordance with the sublicensing rights set forth in Section 3.01. Each external deployment would be customized for the applicable client&rsquo;s specific therapeutic focus, data environment, and research objectives, with the Platform deployed directly within the client&rsquo;s own infrastructure in accordance with Section 2.12.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase 3 &mdash; Platform Expansion</B>. As the client base grows, KALA intends to expand the Platform&rsquo;s capabilities to include advanced predictive modeling for drug discovery workflows, AI-powered hypothesis generation and experimental design, secure regulatory-compliant data management, and collaborative research tools for academic institutions, CROs, and pharmaceutical partners.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the avoidance of doubt, the phased deployment strategy described in this Section 2.13 reflects KALA&rsquo;s current business intentions and does not impose any obligation on KALA to proceed with any particular phase or to achieve any particular results. KALA&rsquo;s decisions regarding the timing, scope, and execution of each phase shall be in its sole and absolute discretion</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE III </B><BR><B>EXCLUSIVITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exclusive
    License &mdash; Biotechnology Field</B><FONT STYLE="font-weight: normal">. For the duration of the Term, Younet hereby grants to
    KALA an exclusive, worldwide license to use, deploy, and sublicense the Platform (as customized and configured under this Agreement)
    solely within the Biotechnology Field. For the avoidance of doubt, KALA holds exclusive worldwide rights to the Platform within the
    Biotechnology Field for the duration of the Term, preventing direct platform competition in such field during the license term. During
    the Term, Younet shall not develop, deploy, license, or otherwise make available to any third party a substantially similar biomedical
    AI research platform for use in the Biotechnology Field without the prior written consent of KALA. KALA shall have the right, without
    the prior consent of Younet (but subject to this Section 3.01), to sublicense access to and use of the Platform to third-party clients
    within the Biotechnology Field, on such terms as KALA determines in its sole discretion, provided that:</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each sublicensee shall execute a sublicense agreement containing terms no less protective of Younet&rsquo;s Background IP and Confidential Information than those set forth in this Agreement;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KALA shall remain responsible for, and shall guarantee, each sublicensee&rsquo;s compliance with the applicable terms of this Agreement;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KALA shall reimburse Younet for all incremental, documented, out-of-pocket infrastructure, hosting, and support costs directly attributable to each sublicensee&rsquo;s use of the Platform, as invoiced monthly by Younet with reasonable supporting detail; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KALA shall provide Younet with written notice within ten (10) business days of KALA&rsquo;s determination to pursue a sublicense with a prospective sublicensee (which notice may be given prior to or after execution of the sublicense), identifying the sublicensee and the general scope of permitted use. Within five (5) business days of receiving such notice, Younet shall deliver to KALA a written estimate of any incremental infrastructure, hosting, technical setup, and staffing costs that Younet reasonably anticipates will be required to onboard and support such sublicensee (a &ldquo;<B>Sublicensee Cost Estimate</B>&rdquo;), which shall be in reasonable detail and limited to documented, incremental costs directly attributable to the sublicensee. KALA shall not be required to delay execution of any sublicense pending receipt of a Sublicensee Cost Estimate. KALA shall reimburse Younet for all reasonable, documented costs set forth in the Sublicensee Cost Estimate (as may be adjusted by mutual written agreement) within thirty (30) days of Younet&rsquo;s invoice therefor, accompanied by reasonable supporting documentation. For the avoidance of doubt, Younet&rsquo;s failure to deliver a Sublicensee Cost Estimate within the five (5) business day period shall not restrict or delay KALA&rsquo;s right to execute the sublicense, and Younet shall not have a right to withhold, delay, or condition any sublicense. </FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the avoidance of doubt, all sublicense fees, royalties, or other revenue received by KALA from sublicensees shall be retained by KALA, and Younet shall have no entitlement to any share of such revenue other than the incremental cost reimbursement described in clause (iii) above and reimbursement for reasonable, documented initial launch costs (including technical setup and dedicated staff time) directly attributable to the onboarding of each sublicensee, as set forth in the applicable Sublicensee Cost Estimate delivered pursuant to Section&#160;3.01(iv), provided that (x) such initial launch costs shall not exceed Twenty-Five Thousand United States Dollars (US$25,000) per sublicensee without KALA&rsquo;s prior written approval, and (y) Younet shall provide KALA with reasonable supporting documentation for all amounts invoiced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Notwithstanding anything to the contrary in this Agreement (including Sections 3.01 and 3.02), the exclusivity and non-compete restrictions in this Article 3 shall apply only to (i) the Researgency Platform (as defined herein) and (ii) the development, deployment, licensing, or making available to any third party of a custom, dedicated, single-tenant, on-premises, private-cloud, or comparable in functionality biomedical AI research platform that is substantially similar to the Platform as customized and configured for KALA for use in the Biotechnology Field. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">For the avoidance of doubt, nothing in this Agreement shall restrict Younet, at any time (including during the Term), from (a) operating, offering, licensing, selling, providing access to, or supporting Younet&rsquo;s standard, generally available, self-serve, multi-tenant SaaS version of the Younet AI platform for any use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exclusivity
    Duration</B><FONT STYLE="font-weight: normal">. The exclusive license granted in Section 3.01 shall remain in effect for the duration
    of the Term (i.e., the Initial Term plus all Renewal Terms, if any). Upon expiration of the Term (including if KALA elects not to
    extend), the exclusive license shall terminate and Younet shall be free to license the Platform in the Biotechnology Field to third
    parties, subject to the survival provisions of Article 11.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carve-Out
    for Younet&rsquo;s General Business</B><FONT STYLE="font-weight: normal">. For the avoidance of doubt, the exclusivity granted hereunder
    applies solely to the Biotechnology Field. Younet retains the unrestricted right to develop, deploy, license, and sell its AI platform,
    agents, and services to clients in all other industries and fields of use, including but not limited to e-commerce, financial services,
    legal, education, marketing, and general enterprise applications.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Compete</B><FONT STYLE="font-weight: normal">.
    During the Term, Younet shall not, directly or indirectly, enter into any agreement, arrangement, or understanding with any third
    party for the development or deployment of a custom biomedical AI research platform substantially similar to the Platform without
    the prior written consent of KALA. This restriction shall not prevent Younet from providing general AI consulting, training, or support
    services that do not involve the development of a competing platform in the Biotechnology Field.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE IV </B><BR><B>COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Initial
    Fee</B><FONT STYLE="font-weight: normal">. In consideration of the Initial Deliverables and the grant of the exclusive license during
    the Initial Term, KALA shall pay Younet a total cash fee of up to Five Hundred Thirty Thousand United States Dollars (US$530,000.00)
    (the &ldquo;</FONT><B>Initial Fee</B><FONT STYLE="font-weight: normal">&rdquo;), payable as follows:</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Upfront Payment</B>. Eighty Thousand United States Dollars (US$80,000.00) (the &ldquo;<B>Upfront Payment</B>&rdquo;), due and payable on execution of this Agreement;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Development Continuation Payments</B>. Subject to Section 4.01(c), Four Hundred Fifty Thousand United States Dollars (US$450,000.00) (the &ldquo;Development Continuation Payments&rdquo;), payable in nine (9) equal monthly installments of Fifty Thousand Dollars (US$50,000.00) each, with the first such installment due on the first business day of the third (3rd) month following the Effective Date and each subsequent installment due on the first business day of each successive month thereafter, through and including the first business day of the eleventh (11th) month following the Effective Date.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Development Continuation Election</B>. The Development Continuation Payments under Section 4.01(b) shall become due and payable only if KALA, in its sole and absolute discretion, delivers written notice to Younet electing to engage Younet for continued development of the Platform (a &ldquo;<B>Development Continuation Notice</B>&rdquo;). KALA may deliver a Development Continuation Notice at any time on or after the first business day of the third (3rd) month following the Effective Date. For the avoidance of doubt, KALA is under no obligation to deliver a Development Continuation Notice, and Younet shall have no claim against KALA for failing to do so. If KALA does not deliver a Development Continuation Notice, the Upfront Payment shall constitute the sole cash component of the Initial Fee and shall be full and complete cash consideration for the Initial Deliverables and the grant of the exclusive license during the Initial Term.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scope of Continued Development Services</B>. Upon delivery of a Development Continuation Notice, the Development Continuation Payments shall cover Younet&rsquo;s continued development, customization, optimization, and enhancement of the Platform during the remainder of the Initial Term, including the allocation of dedicated development personnel and resources as reasonably necessary. The specific development priorities and deliverables for each month shall be agreed in writing between the Parties, acting reasonably.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discontinuation</B>. KALA may discontinue the Development Continuation Payments at any time upon thirty (30) days&rsquo; prior written notice to Younet. Upon such discontinuation, KALA shall pay any installment that has become due prior to the effective date of discontinuation, but shall have no obligation to pay any further installments. Younet&rsquo;s obligation to provide continued development services under this Section 4.01 shall cease upon the effective date of such discontinuation.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Initial Shares.</B> <FONT STYLE="font-weight: normal">In addition to the Initial Fee, KALA shall issue to Younet (or its designee) Five Million (5,000,000) shares of KALA common stock (the &ldquo;</FONT><B>Initial Shares</B><FONT STYLE="font-weight: normal">&rdquo;) within ten (10) business days of the Effective Date. The Initial Shares constitute additional consideration for the Initial Deliverables and the grant of the exclusive license during the Initial Term.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extension Fee.</B> <FONT STYLE="font-weight: normal">If KALA elects to extend this Agreement for a Renewal Term, KALA shall pay Younet the following for each Renewal Term (collectively, the &ldquo;</FONT><B>Extension Fee</B><FONT STYLE="font-weight: normal">&rdquo;):</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash Payment</B>: Two Hundred Fifty Thousand United States Dollars (US$250,000.00), due and payable upon delivery of the Extension Notice; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extension Shares</B>: Five Million (5,000,000) shares of KALA common stock, to be issued within ten (10) business days of KALA&rsquo;s delivery of the Extension Notice.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">For the avoidance of doubt, KALA is under no obligation to pay any Extension Fee or to extend this Agreement beyond the Initial Term. Each Extension Fee is payable only if and when KALA voluntarily elects to extend by delivering an Extension Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share Terms.</B> <FONT STYLE="font-weight: normal">All shares of KALA common stock issued under this Article 4 (whether Initial Shares or Extension Shares, collectively the &ldquo;</FONT><B>Shares</B><FONT STYLE="font-weight: normal">&rdquo;) shall be subject to the following terms and conditions:</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted Securities</B>. The Shares shall be &ldquo;restricted securities&rdquo; as defined under Rule&#160;144 of the Securities Act and shall bear the following restrictive legend:</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SHARES MAY NOT BE OFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND SUCH LAWS.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuance Timing</B>. The Shares shall be issued within ten (10) business days following the Effective Date or the Extension Notice, as applicable.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment Representations</B>. Younet (or its designee) represents and warrants that: (i) it is acquiring the Shares for its own account, for investment purposes only, and not with a view to distribution or resale; (ii) it is an &ldquo;accredited investor&rdquo; as defined in Rule&#160;501(a) of Regulation D under the Securities Act; (iii) it has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of the investment; (iv) it understands that the Shares have not been registered under the Securities Act and may not be resold absent registration or an applicable exemption; and (v) it can bear the economic risk of holding the Shares for an indefinite period.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compliance with Nasdaq Rules</B>. The issuance of the Shares shall be subject to compliance with all applicable Nasdaq Listing Rules, including without limitation Rule&#160;5635(c) and Rule&#160;5635(d). In the event that shareholder approval is required for the issuance of the Shares under applicable Nasdaq rules, the Parties shall cooperate in good faith to obtain such approval or to restructure the equity compensation in a manner that does not require shareholder approval.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&#160;4(a)(2) Exemption</B>. The Shares shall be issued in reliance on the exemption from registration provided by Section&#160;4(a)(2) of the Securities Act and/or Rule&#160;506(b) of Regulation D promulgated thereunder.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Orderly Market Restriction</B>. Younet hereby covenants and agrees that, for the duration of the Term and for a period of twelve (12) months following the expiration or termination of this Agreement (the &ldquo;<B>Restricted Period</B>&rdquo;), Younet shall not, and shall cause its affiliates and designees (including any transferee or nominee that received Shares at Younet&rsquo;s direction) not to, sell, transfer, or otherwise dispose of on any Trading Day a number of shares of KALA common stock (whether received as Initial Shares, or Extension Shares) that exceeds three percent (3%) of the Daily Trading Volume for such Trading Day (the &ldquo;<B>Daily Volume Cap</B>&rdquo;).</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of this Section&#160;4.04(f):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trading Day</B>&rdquo; means any day on which the Nasdaq Stock Market (or such other principal market on which KALA common stock is then listed) is open for trading;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Daily Trading Volume</B>&rdquo; means the total reported trading volume of KALA common stock on the Nasdaq Stock Market (or such other principal market on which KALA common stock is then listed) on the applicable Trading Day, as reported by Nasdaq or a nationally recognized market data provider;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the Daily Trading Volume for any Trading Day is not determinable until after the close of trading, Younet may, for the purpose of compliance with this Section&#160;4.04(f), rely in good faith on the prior Trading Day&rsquo;s reported volume as a reasonable estimate, provided that any excess over the Daily Volume Cap based on actual reported volume shall be cured by reducing sales on the immediately following Trading Day(s) by the excess amount;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales effected pursuant to a bona fide block trade arranged through a registered broker-dealer at a price at or above the then-current market price, with KALA&rsquo;s prior written consent (not to be unreasonably withheld), shall not be subject to the Daily Volume Cap;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Younet shall maintain, and shall cause its broker(s) to maintain, records of all sales of KALA common stock sufficient to demonstrate compliance with this Section&#160;4.04(f), and shall provide such records to KALA within five (5) business days of written request; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any breach of this Section&#160;4.04(f) shall constitute a material breach of this Agreement, entitling KALA, in addition to all other rights and remedies at law or in equity, to seek injunctive relief without the necessity of posting a bond or proving actual damages.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Infrastructure
    and Support Costs</B><FONT STYLE="font-weight: normal">. During the Initial Term, all infrastructure and support costs associated
    with the Initial Deliverables for the first 3 (three) months shall be included in the Upfront Payment and the Initial Shares, and
    no additional monthly payments shall be owed by KALA. Any services outside of initial deliverables including continuous infrastructure
    and maintenance after initial 3 (three) months to be paid by KALA as a direct costs, under prior pre-agreed budget in writing. For
    the avoidance of doubt, the Development Continuation Payments payable under Section 4.01(b) (if elected by KALA) cover continued
    development services only and are separate from and in addition to any infrastructure and maintenance cost obligations under this
    Section 4.05. During each Renewal Term, all infrastructure, support, hosting, and LLM token usage costs shall be paid by KALA, under
    pre-approved budget in writing, unless otherwise agreed in writing.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.06</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional Services.</B> <FONT STYLE="font-weight: normal">Any additional R&amp;D consulting, data science, or custom development services beyond the Renewal Deliverables shall be subject to a separately negotiated written agreement or change order specifying the scope, timeline, and additional compensation for such services</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.07</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Taxes.</B> <FONT STYLE="font-weight: normal">Each Party shall be responsible for its own taxes arising from the transactions contemplated by this Agreement. Younet acknowledges that the receipt of the Shares may give rise to tax obligations and that KALA has not provided, and will not provide, tax advice to Younet in connection therewith.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE V </B><BR><B>ACQUISITION OPTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">5.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant of Option.</B> <FONT STYLE="font-weight: normal">Younet hereby grants to KALA an irrevocable option (the &ldquo;</FONT><B>Acquisition Option</B><FONT STYLE="font-weight: normal">&rdquo;), exercisable at any time during the Term, to acquire all of the issued and outstanding equity interests of Younet (or, at KALA&rsquo;s election, substantially all of the assets of Younet) for a total purchase price of Fifty Five Million United States Dollars (US$55,000,000) (the &ldquo;</FONT><B>Option Price</B><FONT STYLE="font-weight: normal">&rdquo;), subject to the terms of this Article 5.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise.</B> <FONT STYLE="font-weight: normal">KALA may exercise the Acquisition Option by delivering written notice to Younet (an &ldquo;</FONT><B>Option Exercise Notice</B><FONT STYLE="font-weight: normal">&rdquo;) at any time during the Term. Upon delivery of an Option Exercise Notice, the Parties shall negotiate in good faith the definitive terms and conditions of the acquisition (including representations, warranties, covenants, closing conditions, and indemnification) and shall use commercially reasonable efforts to execute a definitive purchase agreement within ninety (90) days of the Option Exercise Notice (or such longer period as the Parties may agree in writing).</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Good Faith Negotiation.</B> <FONT STYLE="font-weight: normal">The Parties acknowledge that the Option Price reflects the aggregate consideration for the acquisition and that the definitive terms, including the allocation of the Option Price between cash and equity (if any), the structure of the transaction, representations and warranties, indemnification, and closing conditions, shall be negotiated in good faith following delivery of the Option Exercise Notice. Neither Party shall unreasonably withhold, condition, or delay its cooperation in such negotiations.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder Approval.</B> <FONT STYLE="font-weight: normal">If the exercise of the Acquisition Option or the consummation of the acquisition requires the approval of the shareholders of either Party under applicable law, stock exchange rules, or the organizational documents of such Party, each Party shall use its best efforts to obtain such approval, including by recommending the transaction to its shareholders, including the transaction in the next available proxy statement or information circular, and soliciting proxies in favor of approval.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulatory Approvals.</B> <FONT STYLE="font-weight: normal">The Parties shall cooperate in good faith to obtain all regulatory approvals required to consummate the acquisition, including any approvals required under applicable antitrust, competition, or foreign investment laws.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.06</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interim Obligations.</B> <FONT STYLE="font-weight: normal">From the date of delivery of an Option Exercise Notice until the earlier of (a) the closing of the acquisition and (b) the termination of negotiations pursuant to Section&#160;5.07, Younet shall conduct its business in the ordinary course consistent with past practice and shall not, without the prior written consent of KALA, (i) issue any equity interests or securities convertible into equity interests, (ii) enter into any material contract outside the ordinary course, (iii) dispose of any material assets, or (iv) take any action that would reasonably be expected to materially impair the value of Younet or the consummation of the acquisition.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.07</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Failure to Agree.</B> <FONT STYLE="font-weight: normal">If the Parties, acting in good faith, are unable to agree on definitive terms within one hundred eighty (180) days of the Option Exercise Notice (or such longer period as the Parties may agree), the Acquisition Option shall remain exercisable during the remainder of the Term and KALA may deliver a subsequent Option Exercise Notice at any time. For the avoidance of doubt, a failure to reach agreement on definitive terms shall not extinguish the Acquisition Option.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.08</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Survival.</B> <FONT STYLE="font-weight: normal">The Acquisition Option shall terminate upon the expiration of the Term. The Acquisition Option is personal to KALA and may not be assigned without the prior written consent of Younet, except in connection with a permitted assignment under Section 12.02.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.09</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competing Purchase Offer; KALA Right of First Refusal.</B> <FONT STYLE="font-weight: normal">If, during the Term, Younet receives a bona fide written offer from a third party to purchase all or substantially all of the equity interests or assets of Younet on terms and conditions, including price, that are substantially similar to those set forth in this Agreement (a &ldquo;</FONT><B>Competing Offer</B><FONT STYLE="font-weight: normal">&rdquo;), Younet shall promptly provide KALA with written notice of such Competing Offer, including a copy of the offer and all material terms. Upon receipt of such notice, KALA shall have thirty (30) days to deliver written notice to Younet stating either (a) that KALA elects to exercise its Acquisition Option pursuant to Section&#160;5.01 on the same terms as the Competing Offer, or (b) that KALA declines to exercise its Acquisition Option, in which case KALA&rsquo;s Acquisition Option shall terminate and Younet shall be free to proceed with the Competing Offer. If KALA does not respond within the thirty (30) day period, KALA shall be deemed to have declined to exercise its Acquisition Option. For the avoidance of doubt, Younet shall not consummate any transaction pursuant to a Competing Offer unless and until KALA has either declined or failed to timely exercise its rights under this Section 5.09.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE VI </B><BR><B>INTELLECTUAL PROPERTY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KALA Data.</B> <FONT STYLE="font-weight: normal">KALA retains all right, title, and interest in and to all KALA Data. Younet shall not use KALA Data for any purpose other than performing its obligations under this Agreement. Upon termination or expiration of this Agreement, Younet shall promptly return or destroy all KALA Data in its possession, custody, or control, and shall certify such return or destruction in writing.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform
    IP &mdash; Work Product.</B> <FONT STYLE="font-weight: normal">All Deliverables, custom AI agents, biomedical-specific configurations,
    training data models, and other work product under Researgency platform developed by Younet specifically for KALA under this Agreement
    (collectively, &ldquo;</FONT><B>Work Product</B><FONT STYLE="font-weight: normal">&rdquo;) shall be the sole and exclusive property
    of KALA. Younet hereby assigns, and agrees to assign, to KALA all right, title, and interest in and to the Work Product, including
    all Intellectual Property rights therein. Younet shall execute all documents and take all actions reasonably necessary to perfect
    KALA&rsquo;s ownership of the Work Product. KALA shall execute all documents and take all actions reasonably necessary to perfect/secure/transfer
    KALA&rsquo;s ownership of the Work Product at Younet direction.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Younet Background IP</B>. <FONT STYLE="font-weight: normal">Younet retains all right, title, and interest in and to the Younet Background IP. To the extent that any Younet Background IP is incorporated into or necessary for the operation of the Platform, Younet hereby grants to KALA a perpetual, irrevocable, worldwide, fully paid-up, but not including infrastructure and continuous support royalty-free license to use, modify at KALA&rsquo;s cost, and sublicense upon Younet&rsquo;s written approval, such approval not to be reasonably withheld, such Younet Background IP solely in connection with KALA&rsquo;s use of the Platform within the Biotechnology Field.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Improvements to Younet Background IP.</B> <FONT STYLE="font-weight: normal">Any improvements, modifications, or enhancements to the Younet Background IP that are developed by Younet in the course of performing services under this Agreement shall be owned by Younet, provided that KALA shall receive a perpetual, irrevocable, royalty-free license to use such improvements solely in connection with the Platform within the Biotechnology Field.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No Reverse Engineering.</B> <FONT STYLE="font-weight: normal">KALA shall not reverse engineer, decompile, or disassemble any Younet Background IP.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.06</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Data Security and Firewall.</B> <FONT STYLE="font-weight: normal">Younet shall implement and maintain commercially reasonable technical and organizational measures to ensure that KALA Data is segregated from data belonging to Younet&rsquo;s other clients, and that no KALA Data is used to train, improve, or benefit any AI models or platforms deployed for third parties.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Without limiting the generality of the foregoing, the Platform shall be configured and operated in accordance with the Data Sovereignty principles set forth in Section 2.12(b), such that no KALA Data (or data of any sublicensee) is transmitted to, stored on, or processed by any external servers, public cloud environments (except as expressly permitted under Section&#160;1.03), or third-party AI services. All Platform processing, data storage, and AI inference shall occur within the applicable client&rsquo;s own secure infrastructure; provided, however, that the Parties acknowledge that prior to achievement of full SOC 2 Type II certification, certain non-proprietary, non-confidential data processing functions (such as general biomedical literature queries using publicly available information only) may be routed through Younet&rsquo;s standard LLM interface, subject to the following conditions: (a) no KALA Data, Confidential Information, client proprietary data, trade secrets, clinical data, or patient data shall be transmitted through such interface under any circumstances; (b) KALA shall approve in writing the categories of data and query types permitted to be processed through such interface; (c) Younet shall implement technical controls to prevent the inadvertent transmission of restricted data; and (d) upon achievement of SOC 2 Type II certification (or equivalent), all data processing shall transition to fully on-premises or KALA-approved private cloud infrastructure within sixty (60) days, and the foregoing exception shall automatically terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Without limiting the foregoing, Younet shall implement and maintain the following security measures, which shall be operative from and after the Effective Date (or, with respect to items requiring SOC 2 certification, from and after the SOC 2 Compliance Date).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SOC 2 Timeline</B><FONT STYLE="font-weight: normal">. Younet shall initiate the SOC 2 Type II certification process within thirty (30) days of the Effective Date, using an independent third-party audit firm mutually agreed upon by the Parties (such agreement not to be unreasonably withheld). Younet shall use commercially reasonable efforts to achieve SOC 2 Type II certification (or substantially equivalent independent security certification) within nine (9) months of the Effective Date (the &ldquo;</FONT><B>SOC 2 Compliance Date</B><FONT STYLE="font-weight: normal">&rdquo;). Younet shall provide KALA with quarterly written progress reports on the status of the certification process. If Younet does not achieve SOC 2 Type II certification within twelve (12) months of the Effective Date, KALA shall have the right, without prejudice to its other remedies, to engage an independent security auditor (at Younet&rsquo;s expense) to assess the Platform&rsquo;s security posture and to require Younet to implement any remediation measures identified by such auditor within a commercially reasonable timeframe.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Notwithstanding the SOC 2 timeline, the following security measures shall be implemented by Younet from and after the Effective Date (regardless of the status of SOC 2 certification):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">encrypt all KALA Data at rest (using AES-256 or equivalent) and in transit (using TLS 1.2 or higher);</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">implement and maintain access controls, including multi-factor authentication, role-based access permissions, and logging of all access to KALA Data;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain a written information security program that includes administrative, technical, and physical safeguards designed to protect the confidentiality, integrity, and availability of KALA Data, consistent with industry standards (including, without limitation, SOC 2 Type II or ISO 27001, or substantially equivalent standards);</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct vulnerability assessments and penetration testing of the Platform at least annually (or promptly following any material change to the Platform architecture), and promptly remediate any critical or high-severity vulnerabilities identified;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain an incident response plan and notify KALA in writing within forty-eight (48) hours of Younet becoming aware of any actual or reasonably suspected unauthorized access to, disclosure of, or loss of KALA Data (a &ldquo;Security Incident&rdquo;), and cooperate with KALA in investigating and remediating any such Security Incident; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure that all Younet personnel and subcontractors with access to KALA Data are bound by written confidentiality and data protection obligations no less restrictive than those set forth in this Agreement.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.07</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audit Rights.</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon not less than thirty (30) days&rsquo; prior written notice, KALA (or a qualified independent third-party auditor selected by KALA and reasonably acceptable to Younet) shall have the right, no more than once per twelve (12)-month period during the Term and for one (1) year following expiration or termination, to audit Younet&rsquo;s compliance with its data security, data segregation, and confidentiality obligations under this Agreement. Such audit shall be conducted during normal business hours, at KALA&rsquo;s expense, and shall be subject to reasonable confidentiality restrictions to protect Younet&rsquo;s proprietary information and the information of Younet&rsquo;s other clients.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Younet shall cooperate reasonably with any such audit, including by providing access to relevant systems, records, logs, security documentation, and personnel. Younet shall not be required to provide access to source code of Younet Background IP or to information relating to Younet&rsquo;s other clients.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If an audit reveals a material deficiency in Younet&rsquo;s compliance with its obligations under Sections 5.06 or 7, Younet shall prepare and deliver to KALA a written remediation plan within fifteen (15) business days of receiving written notice of such deficiency and shall use commercially reasonable efforts to complete such remediation within thirty (30) days thereafter. If the deficiency is not remediated within such period, KALA may, without prejudice to its other rights and remedies, conduct a follow-up audit at Younet&rsquo;s expense.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In lieu of a full on-site audit, Younet may, at its option, provide KALA with a current SOC 2 Type II report (or equivalent independent third-party certification) covering the systems and controls applicable to the Platform and KALA Data. If KALA reasonably determines that such report does not adequately address KALA&rsquo;s audit concerns, KALA shall retain the right to conduct a direct audit as described in Section 5.07(a).</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE VII </B><BR><B>CONFIDENTIALITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Obligations.</B> <FONT STYLE="font-weight: normal">Each Party agrees to hold in strict confidence all Confidential Information received from the other Party and to use such Confidential Information solely for the purposes of performing its obligations or exercising its rights under this Agreement. Neither Party shall disclose Confidential Information to any third party without the prior written consent of the disclosing Party, except to its employees, contractors, advisors, and agents who have a need to know and who are bound by confidentiality obligations no less restrictive than those set forth herein.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exceptions.</B> <FONT STYLE="font-weight: normal">Confidential Information shall not include information that: (a) is or becomes publicly available through no fault of the receiving Party; (b) was known to the receiving Party prior to disclosure; (c) is independently developed by the receiving Party without use of or reference to the disclosing Party&rsquo;s Confidential Information; or (d) is rightfully received from a third party without restriction.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compelled Disclosure.</B> <FONT STYLE="font-weight: normal">If a receiving Party is compelled by law, regulation, or legal proceeding to disclose Confidential Information, it shall provide prompt written notice to the disclosing Party (to the extent permitted by law) and shall cooperate with the disclosing Party&rsquo;s efforts to obtain a protective order or other appropriate remedy.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Duration.</B> <FONT STYLE="font-weight: normal">The confidentiality obligations set forth in this Article 7 shall survive the expiration or termination of this Agreement for a period of three (3) years, provided that obligations with respect to trade secrets shall survive for so long as such information remains a trade secret under applicable law.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Public Company Obligations.</B> <FONT STYLE="font-weight: normal">Younet acknowledges that KALA is a publicly traded company subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Nasdaq Stock Market. Younet agrees not to trade in KALA securities while in possession of material, non-public information received in connection with this Agreement, and to comply with all applicable insider trading laws and regulations.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE VIII </B><BR><B>REPRESENTATIONS AND WARRANTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mutual Representations.</B> <FONT STYLE="font-weight: normal">Each Party represents and warrants to the other that: (a) it is duly organized, validly existing, and in good standing under the laws of its jurisdiction of organization; (b) it has the full corporate power and authority to enter into and perform its obligations under this Agreement; (c) the execution, delivery, and performance of this Agreement have been duly authorized; and (d) this Agreement constitutes a valid and binding obligation, enforceable against it in accordance with its terms.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Younet Representations.</B> <FONT STYLE="font-weight: normal">Younet further represents and warrants that:</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it has the technical expertise, personnel, and resources necessary to perform the services and deliver the Deliverables in accordance with this Agreement;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Platform, as delivered, will materially conform to the specifications set forth in Exhibit A for a period of twelve (12) months following acceptance (the &ldquo;<B>Warranty Period</B>&rdquo;);</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Deliverables will not infringe, misappropriate, or violate the Intellectual Property rights of any third party;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it will perform the services in a professional and workmanlike manner, consistent with industry standards;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it has not entered into, and during the Term will not enter into, any agreement or arrangement that would conflict with or impair its ability to perform its obligations or grant the exclusivity rights set forth in Article 3;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">during the Warranty Period, Younet shall use commercially reasonable efforts to correct any material defect in the Platform reported by KALA in writing within thirty (30) days of receiving such report (or such longer period as may be reasonably required given the nature of the defect, provided that Younet promptly commences corrective efforts and keeps KALA reasonably informed of progress). If Younet is unable to correct a material defect within such period, KALA shall be entitled, as its sole remedy under this Section 7.02(f), to a pro-rata credit against any fees then owing to Younet for the period during which the defect materially impairs KALA&rsquo;s use of the Platform; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the Term, Younet shall use commercially reasonable efforts to maintain Platform availability of not less than ninety-five percent (95%) uptime per calendar month, measured exclusive of scheduled maintenance windows (which Younet shall notify KALA of at least forty-eight (48) hours in advance) and Force Majeure events. In the event Platform availability falls below ninety-five percent (95%) in any calendar month, Younet shall promptly investigate and provide KALA with a written remediation plan within ten (10) business days.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KALA Representations.</B> <FONT STYLE="font-weight: normal">KALA further represents and warrants that:</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It has the right to provide the KALA Data to Younet for use in connection with the development of the Platform;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The issuance of the Shares has been duly authorized by the Company&rsquo;s Board of Directors and, to the extent required, by its stockholders;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon issuance, the Shares will be validly issued, fully paid, and non-assessable.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE IX </B><BR><B>INDEMNIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Younet Indemnification.</B> <FONT STYLE="font-weight: normal">Younet shall defend, indemnify, and hold harmless KALA, its directors, officers, employees, and agents from and against any and all claims, losses, damages, liabilities, costs, and expenses (including reasonable attorneys&rsquo; fees) arising from or related to: (a) Younet&rsquo;s breach of any representation, warranty, or obligation under this Agreement; (b) any claim that the Deliverables (excluding KALA Data) infringe the Intellectual Property rights of a third party; or (c) Younet&rsquo;s negligence or willful misconduct.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KALA Indemnification.</B> <FONT STYLE="font-weight: normal">KALA shall defend, indemnify, and hold harmless Younet, its directors, officers, employees, and agents from and against any and all claims, losses, damages, liabilities, costs, and expenses (including reasonable attorneys&rsquo; fees) arising from or related to: (a) KALA&rsquo;s breach of any representation, warranty, or obligation under this Agreement; (b) any claim arising from KALA&rsquo;s use of the Platform or KALA Data; or (c) KALA&rsquo;s negligence or willful misconduct.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitation of Liability.</B> <FONT STYLE="font-weight: normal">EXCEPT FOR BREACHES OF ARTICLE 7 (CONFIDENTIALITY), ARTICLE 6 (INTELLECTUAL PROPERTY), OR OBLIGATIONS UNDER SECTIONS 8.01(b) OR 8.02(b), IN NO EVENT SHALL EITHER PARTY&rsquo;S TOTAL AGGREGATE LIABILITY UNDER THIS AGREEMENT EXCEED THE TOTAL COMPENSATION PAID OR PAYABLE UNDER ARTICLE 4 (INCLUSIVE OF THE FAIR MARKET VALUE OF THE SHARES ON THE DATE OF ISSUANCE). IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE, OR EXEMPLARY DAMAGES, REGARDLESS OF THE FORM OF ACTION OR THEORY OF LIABILITY.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE X </B><BR><B>ONGOING SUPPORT AND MAINTENANCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Initial Term Support.</B> <FONT STYLE="font-weight: normal">During the Initial Term, Younet shall provide KALA with reasonable technical support in connection with the Initial Deliverables (Working Platform and Access), including assistance with access, basic troubleshooting, and orientation. No dedicated development personnel or material infrastructure resources are required of Younet during the Initial Term beyond what is necessary to maintain the Platform.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Renewal Term Support.</B> <FONT STYLE="font-weight: normal">During each Renewal Term, Younet shall provide KALA with ongoing infrastructure support, platform maintenance, and technical assistance as part of the Renewal Deliverables. The scope and level of support for each Renewal Term shall be as set forth in the applicable Extension Notice or as otherwise agreed in writing.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional Agent Development.</B> <FONT STYLE="font-weight: normal">The Parties may mutually agree to the development of additional custom AI agents or platform enhancements beyond the Initial and Renewal Deliverables, subject to the execution of a written change order or amendment specifying the scope, timeline, and additional compensation for such work.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Training.</B> <FONT STYLE="font-weight: normal">Younet shall provide customary as per Younet standards training during the Initial Term (included in the Upfront Payment) and regular continuing training during each Renewal Term (included in the Extension Fee), in each case on the use and administration of the Platform.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE XI </B><BR><B>TERM AND TERMINATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term.</B> <FONT STYLE="font-weight: normal">This Agreement shall commence on the Effective Date for the Initial Term of twelve (12) months. The Agreement shall automatically expire at the end of the Initial Term unless KALA delivers an Extension Notice and pays the applicable Extension Fee to extend for a Renewal Term. Each Renewal Term shall be twelve (12) months in duration and shall similarly expire at its conclusion unless KALA again delivers an Extension Notice and pays the applicable Extension Fee. There is no limit on the number of successive Renewal Terms.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration without Extension.</B> <FONT STYLE="font-weight: normal">If KALA does not deliver an Extension Notice prior to the expiration of the Initial Term or any Renewal Term, this Agreement shall expire automatically at the end of such term. Upon such expiration: (a) the exclusive license under Article 3 shall terminate; (b) Younet shall have no further obligation to provide Renewal Deliverables or support; (c) KALA shall retain ownership of all Work Product delivered and accepted prior to expiration; and (d) Younet shall retain all compensation received prior to expiration. Neither Party shall have any liability to the other for KALA&rsquo;s election not to extend.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Termination for Cause.</B> <FONT STYLE="font-weight: normal">Either Party may terminate this Agreement upon thirty (30) days&rsquo; prior written notice if the other Party materially breaches any provision of this Agreement and fails to cure such breach within such thirty (30)-day notice period.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Termination for Insolvency.</B> <FONT STYLE="font-weight: normal">Either Party may terminate this Agreement immediately upon written notice if the other Party: (a) becomes insolvent; (b) files a petition in bankruptcy or has such a petition filed against it that is not dismissed within sixty (60) days; or (c) makes an assignment for the benefit of creditors.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effects of Termination.</B> <FONT STYLE="font-weight: normal">Upon termination or expiration of this Agreement: (a) all licenses granted to Younet with respect to KALA Data shall immediately terminate; (b) all licenses granted to KALA with respect to Younet Background IP shall survive in accordance with their terms; (c) all Work Product completed as of the date of termination shall be delivered to and owned by KALA, with KALA responsible for any technical, infrastructure, or migration costs associated with such delivery; (d) Articles 4 (to the extent Shares have been issued), Article 5 (Acquisition Option), 6 (including Sections 5.06 and 5.07), 7, 8, 9, and 12 shall survive termination.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE XII </B><BR><B>GENERAL PROVISIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent Contractor.</B> <FONT STYLE="font-weight: normal">Younet is an independent contractor and not an employee, agent, partner, or joint venturer of KALA. Nothing in this Agreement shall be construed as creating an employer-employee, partnership, or joint venture relationship between the Parties.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assignment.</B> <FONT STYLE="font-weight: normal">Neither Party may assign this Agreement or any of its rights or obligations hereunder without the prior written consent of the other Party, except that KALA may assign this Agreement to a successor in connection with a merger, acquisition, or sale of all or substantially all of its assets.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Governing Law.</B> <FONT STYLE="font-weight: normal">This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to any choice-of-law or conflict-of-law rules or provisions.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dispute Resolution.</B> <FONT STYLE="font-weight: normal">Any dispute arising out of or relating to this Agreement shall be resolved by binding arbitration administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules. The prevailing Party in any such proceeding shall be entitled to recover its reasonable attorneys&rsquo; fees and costs.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notices</B>. <FONT STYLE="font-weight: normal">All notices under this Agreement shall be in writing and shall be deemed duly given when delivered personally, sent by nationally recognized overnight courier, or sent by email (with confirmation of receipt) to the Parties at the addresses set forth in the preamble or to such other address as a Party may designate by written notice.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.06</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Entire Agreement.</B> <FONT STYLE="font-weight: normal">This Agreement, together with all Exhibits hereto, constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements, understandings, negotiations, and discussions, whether oral or written.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.07</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment.</B> <FONT STYLE="font-weight: normal">This Agreement may not be amended, modified, or supplemented except by a written instrument executed by authorized representatives of both Parties.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.08</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Waiver.</B> <FONT STYLE="font-weight: normal">No failure or delay by either Party in exercising any right or remedy under this Agreement shall constitute a waiver thereof.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.09</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Severability.</B> <FONT STYLE="font-weight: normal">If any provision of this Agreement is held to be invalid, illegal, or unenforceable, the remaining provisions shall remain in full force and effect.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Counterparts.</B> <FONT STYLE="font-weight: normal">This Agreement may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Electronic signatures shall be deemed original signatures for all purposes.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Force Majeure.</B> <FONT STYLE="font-weight: normal">Neither Party shall be liable for any failure or delay in the performance of its obligations under this Agreement to the extent such failure or delay is caused by circumstances beyond its reasonable control, including but not limited to acts of God, natural disasters, war, terrorism, pandemics, government actions, or failure of third-party infrastructure.</FONT></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">[<I>remainder of page left intentionally blank</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Agreement as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; vertical-align: bottom"><B>KALA BIO, INC.</B></TD></TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: left"><I>/s/ Avraham Minkowitz</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 5%">Name:</TD>
    <TD STYLE="text-align: left; width: 41%">Avraham Minkowitz</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="text-align: left">Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; vertical-align: bottom"><B>2624465 ONTARIO INC.</B></TD></TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: left"><I>/s/&nbsp;Alex Kapralov</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left">Alex Kapralov</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="text-align: left">Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT A &mdash; SCOPE OF WORK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be delivered by Younet to KALA as part of the Researgency Platform Project</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fully Functional Researgency Platform</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery of a production-ready, fully operational Researgency biomedical AI research platform, configured for KALA&rsquo;s use cases.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separate Hosting Infrastructure (Private Cloud)</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deployment of the Researgency platform on a dedicated, private cloud environment, ensuring data segregation and enhanced security for KALA.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separate LLM Infrastructure (Private Cloud)</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of a dedicated large language model (LLM) infrastructure, hosted in a private cloud instance, isolated from other Younet clients.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access Keys and Platform Control Access</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of secure access keys and implementation of robust platform access controls, enabling KALA to manage user permissions and platform administration.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agent Brain Module with Training Features</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery of the Agent Brain module, supporting the following training modalities:</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documentary Training: Upload and ingestion of documents for agent knowledge base expansion.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Textual Training: Direct text input for agent learning and contextual adaptation.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Live Chat Training: Real-time chat-based training sessions to refine agent responses.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrated Email (Gmail) Training: Ingestion and analysis of email content (via Gmail integration) for agent training purposes. Gmail module timeline may be longer than initial deliverable timeline, due to Google certification required for new domains.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agent Settings Module</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implementation of an Agent Settings module, enabling agent customization in accordance with Younet&rsquo;s standard configuration options.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Speak to Product&rdquo; Module</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deployment of a &ldquo;Speak to Product&rdquo; module, allowing users to generate real-time QR codes for instant agent sharing and onboarding functionality.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agent Sharing Module</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery of an Agent Sharing module, supporting both private and public link sharing of agents, with configurable access controls.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 25; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On-Premises Deployment Capability</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Platform architecture designed and configured to support full On-Premises Deployment within each client&rsquo;s own secure computing environment, with no data transmitted to external servers, public clouds, or third-party AI services, consistent with the Data Sovereignty principles set forth in Section 2.12(b).</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multi-Client Scalability Architecture</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Platform architecture designed from inception for multi-client deployment, enabling KALA to onboard additional biotech and pharmaceutical sublicensees without material rebuilding of core Platform systems.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomedical RAG Pipeline Infrastructure</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced retrieval-augmented generation (RAG) pipelines optimized for biomedical and pharmaceutical datasets, enabling the Platform to retrieve, synthesize, and analyze information from proprietary client data, published scientific literature, and regulatory databases.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KALA Internal Validation Configuration</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial configuration and adaptation of the Platform for application to KALA&rsquo;s proprietary MSC-S platform datasets, KPI-012 preclinical and clinical data, and existing intellectual property portfolio, to support KALA&rsquo;s internal validation and AI-driven reassessment of historical datasets during the Initial Term.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All deliverables will be provided in accordance with the specifications and acceptance criteria set forth in this Exhibit A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT B &mdash; MILESTONE SCHEDULE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Milestone</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Target
    Date</B></FONT></TD>
    <TD STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment
    Trigger</B></FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Term &mdash; Milestone 1</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Platform Access (standalone cloud instance + web interface)</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective Date + 5 days</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront Payment ($80,000) + Initial Shares (5,000,000) &mdash; due on execution. Development Continuation Payments ($50,000/month &#xd7; 9 months) commence in month 3 only upon KALA&rsquo;s delivery of a Development Continuation Notice.</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Term &mdash; Milestone 2</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Platform Delivery (working platform with bio-med LLM agent functionality)</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective Date + 10 days</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in Initial Fee</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Renewal Term</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full deployment, RAG optimization, custom agent development, ongoing support</FONT></P> </TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commences upon Extension Notice + Extension Fee</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extension Fee ($250,000) + Extension Shares (5,000,000)</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent Renewal Terms</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continued development, support, enhancements, additional agents as agreed</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each 12-month period upon Extension Notice + Extension Fee</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extension Fee ($250,000) + Extension Shares (5,000,000) per Renewal Term</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 27; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>kalabio_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
   <HEAD>
      <TITLE></TITLE>
   </HEAD>
   <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KALA
      BIO Announces Strategic Initiative to Deploy and Continue to Develop an</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>On-Premises AI Infrastructure Platform for the Biotech
      Industry; Enters Into</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform Development and Exclusive License Agreement for Proprietary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AI Research Platform &ldquo;Researgency&rdquo;</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9679;</I></B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Company
            launches initiative to become a dedicated AI infrastructure partner for the biotechnology industry &mdash; to deploy secure,
            on-premises AI systems directly within client environments where proprietary data never leaves the client&rsquo;s control</I></B></FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9679;</I></B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Platform-as-a-service
            model designed to generate recurring revenue by licensing AI capabilities to biotech and pharmaceutical companies of all
            sizes &mdash; addressing a market where the top 20 pharma companies invested approximately $167 billion in R&amp;D in 2024
            but have only recently begun to deploy meaningful AI budgets</I></B></FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9679;</I></B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>KALA
            to serve as its own first deployment client, applying Researgency to its proprietary MSC-S biological datasets and KPI-012
            clinical program before scaling to external biotech partners</I></B></FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9679;</I></B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusive
            worldwide license secured for the Researgency platform in the biotechnology field for an initial 12-month term with successive
            renewal options; platform architecture designed from inception for multi-client deployment</I></B></FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9679;</I></B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>On-premises,
            data-sovereign architecture will differentiate Researgency from centralized AI platforms &mdash; will enable biotechs to
            leverage institutional-grade AI without surrendering control of their most valuable intellectual property</I></B></FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARLINGTON,
      Mass., March&#160;4, 2026 (GLOBE NEWSWIRE)</B> &mdash; KALA BIO, Inc. (NASDAQ: KALA) (&ldquo;<B>KALA</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;),
      a clinical-stage biopharmaceutical company, today announced a strategic initiative to build a biotechnology industry dedicated,
      on-premises artificial intelligence (&ldquo;<B>AI</B>&rdquo;) infrastructure platform, designed to be deployed directly within
      biotech and pharmaceutical client environments, enabling companies across the life sciences sector to unlock additional potential
      of their proprietary biological data without ever surrendering control of it.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      Company also announced that it has entered into a Platform Development and Exclusive License Agreement (the &ldquo;<B>Agreement</B>&rdquo;)
      with 2624465 Ontario Inc., operating as Younet AI (&ldquo;<B>Younet</B>&rdquo;), for a proprietary AI research platform, internally
      designated &ldquo;Researgency,&rdquo; designed to deploy custom, secure, large language models (&ldquo;<B>LLMs</B>&rdquo;) purpose-built
      for biomedical research and data science applications. The Agreement provides KALA with initial platform access during a 12-month
      initial term and the option, in KALA&rsquo;s sole discretion, to extend the Agreement for successive 12-month renewal terms.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
      Vision: AI Infrastructure for the Entire Biotech Industry</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      biotechnology industry faces a fundamental structural problem: thousands of small and mid-cap biotech companies are generating
      enormous volumes of proprietary biological data, from preclinical studies, clinical trials, genomic sequencing, protein interaction
      mapping, and secretome analysis, but the vast majority of these companies lack the internal resources, infrastructure, or specialized
      talent to deploy advanced AI capabilities against that data. At the same time, these companies are rightly unwilling to surrender
      their most sensitive intellectual property, the biological data, trade secrets, and clinical datasets that represent years of investment
      and form the core of their competitive advantage, to centralized, third-party cloud platforms.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KALA
      intends to solve this problem. The Company&rsquo;s vision is to serve as a dedicated AI infrastructure partner for the biotechnology
      industry, deploying the Researgency platform directly within each client&rsquo;s own secure environment, on their own servers,
      under their own control. In this model, KALA would provide the AI platform, the purpose-built biomedical agents, and the ongoing
      optimization, while the client would retain full ownership and custody of their data at all times. No proprietary information would
      ever leave the client&rsquo;s infrastructure. No biological data would be shared with public AI services.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      Company believes this on-premises, data-sovereign approach represents a fundamentally different model from the centralized AI platforms
      currently operating in the life sciences space. While established AI drug discovery companies, including well-funded, publicly
      traded platforms with billion-dollar market capitalizations, typically require clients to upload proprietary data to centralized
      cloud environments, KALA&rsquo;s architecture is designed from inception to go to the client, not the other way around. The Company
      believes this distinction is critical in an industry where intellectual property, trade secrets, and regulatory-sensitive data
      represent the most valuable assets a company possesses. Younet&rsquo;s current go to market strategy is focused on morphing and
      tech augmenting existing operating companies into Agentic Companies where a large bulk of repeat and time consuming tasks and research
      are passed on to teams of proprietary agents. KALA intends to build on top of this approach and implement Agentic Company strategy
      in biomedical field.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
      are not building another centralized AI platform that asks biotechs to hand over their crown jewels,&rdquo; said Avi Minkowitz,
      Chief Executive Officer of KALA BIO. &ldquo;We are building the opposite. We want to be the company that shows up at the biotech
      company&rsquo;s door, deploys institutional-grade AI on the biotech company&rsquo;s servers, makes the biotech company&rsquo;s
      data smarter, and never takes it from the biotech company. Hundreds of biotech companies are sitting on proprietary biological
      data that could yield breakthrough insights, but they cannot build this infrastructure themselves, and they should not have to
      trust a third party with their most sensitive assets. That is the gap we are filling. We intend to be an AI backbone of the biotech
      industry.&rdquo;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
      Market Opportunity: A $167+ Billion R&amp;D Ecosystem Underserved by AI</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global AI drug discovery market is projected to grow at a compound annual growth rate approximately 25%,<SUP>1</SUP> driven by AI&rsquo;s
demonstrated ability to compress traditional drug development timelines, which historically average 10 to 15 years and cost up to $2.6
billion per approved drug,<SUP>2</SUP> to potentially as little as 12 to 18 months for preclinical candidate nomination,</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      Company has not independently verified the data or projections from third-party sources cited below. Such data involves risks and
      uncertainties and is subject to change based on various factors.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">Mordor Intelligence, <I>Artificial Intelligence in Drug Discovery
Market &mdash; Size, Share &amp; Trends Analysis Report</I> (February&#160;2026), estimating a CAGR of 25.94% from 2026&ndash;2031. See
also Grand View Research, <I>Artificial Intelligence in Drug Discovery Market Report, 2026&ndash;2033</I> (October&#160;2024), estimating
a CAGR of 24.8%.</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deloitte,
Measuring the Return from Pharmaceutical Innovation (March&#160;2025), reporting an average cost of $2.23 billion per drug for the world&rsquo;s
20 largest pharmaceutical companies in 2024. See also Mulcahy, A. et al., &ldquo;Use of Clinical Trial Characteristics to Estimate Costs of
New Drug Development,&rdquo; JAMA Network Open, Vol. 8, No. 1, e2453275 (January&#160;2025), estimating a mean R&amp;D cost of $1.31 billion
per new drug approved by the FDA in 2019, after adjusting for cost of capital and discontinued products. Drug development timelines of
10 to 15 years are widely reported in peer-reviewed literature and industry analyses. See, e.g., U.S. Department of Health and Human
Services, ASPE, Drug Development (October&#160;2024); Human Specific Research, The Reality of Drug Discovery and Development (November&#160;2025).</FONT></TD>
</TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0">while reducing costs by an estimated 30 to 40 percent.<SUP>3</SUP> Dozens of AI-designed drug candidates are currently in clinical
      trials globally, up from only three in 2016,<SUP>4</SUP> with the first AI-discovered drug approvals anticipated in the near term.</P>

<P STYLE="margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      world&rsquo;s twenty largest pharmaceutical companies collectively invested approximately $167 billion in research and development in
      2024,<SUP>5</SUP> yet the pharmaceutical industry&rsquo;s combined investment in AI-driven drug discovery was estimated at approximately
      $4 billion in 2025, expected to grow to approximately $25 billion by 2030.<SUP>6</SUP> The Company believes this represents one
      of the largest technology adoption gaps in any major industry.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
      importantly, the Company believes the addressable market for on-premises, secure, purpose-built AI infrastructure, specifically
      designed for small and mid-cap biotech companies that cannot afford to build in-house AI capabilities and are unwilling to send
      proprietary data to centralized platforms, is substantially underserved. There are over 3,200 biotechnology companies in the United
      States alone,<SUP>7</SUP> the majority of which are generating biological data that could benefit from AI-driven analysis but lack
      a viable, secure path to deploying it. KALA believes this segment represents a significant near-term revenue opportunity for a
      platform specifically architected to serve their needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
      Is Researgency and How Does It Work?</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Researgency
      is a proprietary biomedical AI research platform licensed to KALA by Younet AI, a specialized artificial intelligence development
      firm with experience deploying over 100 custom AI agents for enterprise clients across healthcare, technology, and life sciences
      sectors.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      platform is expected to be capable of deploying fully on-premises, secure AI systems that operate independently of any public AI
      service. In practical terms, Researgency works as follows: instead of relying on large teams of researchers to manually review
      thousands of scientific papers, clinical datasets, and biological records, a biotech company deploys purpose-built AI &ldquo;agents&rdquo;,
      specialized digital assistants trained exclusively on biomedical and pharmaceutical data, that can perform these tasks faster,
      more comprehensively, and at a fraction of the cost. Each agent is designed for a specific research function, such as analyzing
      protein interactions, reviewing drug safety literature, identifying new therapeutic targets, or modeling clinical trial outcomes.
      Intended narrow specialty of the agents shall significantly reduce hallucinations and save time on error corrections.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">McKinsey
&amp; Company, <I>Generative AI in the Pharmaceutical Industry: Moving from Hype to Reality</I> (January&#160;2024), estimating up to
50% cost reductions in clinical trial processes, and FounderNest, citing McKinsey &amp; Company and industry data, reporting AI platforms
can cut drug discovery costs by up to 40% and compress timelines from 5&ndash;6 years to 12&ndash;18 months for preclinical candidate
nomination.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>4</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jayatunga,
M.K.P. et al., &ldquo;AI in small-molecule drug discovery: A coming wave?&rdquo; <I>Nature Reviews Drug Discovery</I> (2022), as cited in the CAS
Insights report, &ldquo;AI Drug Discovery: Assessing the First AI-Designed Drug Candidates to Go into Human Clinical Trials&rdquo; (June&#160;2024).
See also PMC, &ldquo;AI In Action: Redefining Drug Discovery and Development&rdquo; (February&#160;2025), documenting growth from 3 AI-designed clinical
candidates in 2016 to 67 by 2023.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>5</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hardman
&amp; Co, <I>2024 Pharma Statistics</I> (April&#160;2025). Cumulative R&amp;D spend by the top 20 pharmaceutical companies by sales was
$166.8 billion in 2024 ($153.1 billion in 2023). Total R&amp;D spend across Hardman &amp; Co&rsquo;s universe of 45 pharma companies was $194.3
billion in 2024.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>6</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FounderNest,
<I>Pharma at an Inflection Point: Investment Trends 2024&ndash;2025</I> (December&#160;2025), reporting that 95% of pharmaceutical companies
now invest in AI, with aggregate AI spending expected to grow from approximately $4 billion in 2025 to $25 billion by 2030. See also
McKinsey &amp; Company (January&#160;2024), estimating generative AI could generate $60 billion to $110 billion in annual economic value
for the pharmaceutical and medical-product industries.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>7</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IBISWorld,
<I>Biotechnology in the US &mdash; Number of Businesses</I> (2025), reporting 3,229 biotechnology businesses in the United States as
of 2025 (NAICS classification).</FONT></TD>
</TR></TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      platform&rsquo;s core architecture includes advanced retrieval-augmented generation (&ldquo;<B>RAG</B>&rdquo;) pipelines, scalable
      AI infrastructure, and proprietary training algorithms that have been validated through a completed feasibility study confirming
      adaptability to the complex analytical demands of biomedical research, drug discovery, and clinical data science.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
      technical differentiators include:</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>On-Premises
            Deployment:</B> The entire AI system operates within the client&rsquo;s own secure infrastructure. No data is transmitted
            to external servers, public clouds, or third-party AI services.</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Custom
            Agent Architecture:</B> Purpose-built AI agents are configured specifically for each client&rsquo;s therapeutic focus areas,
            data types, and research objectives, not generic, one-size-fits-all models.</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Full
            Data Sovereignty:</B> Proprietary biological data, trade secrets, and intellectual property remain entirely under the client&rsquo;s
            control at all times, meeting the highest standards of regulatory compliance and IP protection.</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scalable
            Infrastructure:</B> Platform architecture is designed from inception for multi-client deployment, enabling KALA to onboard
            additional biotech clients without rebuilding core systems.</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
      Platform Revenue Model: From Internal Tool to Industry Infrastructure</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KALA
      intends to deploy the Researgency platform in a phased approach designed to validate performance, demonstrate value, and scale
      across the biotechnology industry:</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
      1 &mdash; Internal Validation (Current):</B> KALA serves as its own first deployment client, applying Researgency&rsquo;s AI capabilities
      to the Company&rsquo;s proprietary MSC-S platform datasets, KPI-012 preclinical and clinical data, and existing intellectual property
      portfolio. The Company expects to complete its initial AI-driven reassessment of historical datasets and report preliminary findings
      during the 12-month initial term.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
      2 &mdash; External Deployment:</B> Following successful internal validation, KALA intends to begin licensing the Researgency platform
      to external biotech and pharmaceutical clients on a recurring subscription basis. Each deployment would be customized for the client&rsquo;s
      specific therapeutic focus, data environment, and research objectives, with the platform installed directly on the client&rsquo;s
      own infrastructure.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
      3 &mdash; Platform Expansion:</B> As the client base grows, KALA intends to expand Researgency&rsquo;s capabilities to include
      advanced predictive modeling for drug discovery workflows, AI-powered hypothesis generation and experimental design, secure regulatory-compliant
      data management, and collaborative research tools for academic institutions, CROs, and pharmaceutical partners.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
      phased approach is designed to transform KALA from a single-pipeline clinical-stage biopharmaceutical company into a <B>platform
      company with recurring, scalable revenue</B> derived from licensing AI infrastructure to the broader biotechnology industry, while
      simultaneously enhancing the value of KALA&rsquo;s own therapeutic programs.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competitive
      Positioning: Why On-Premises Matters</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      Company believes the current AI drug discovery landscape is dominated by centralized platform models that require biotech companies
      to upload proprietary data to third-party cloud environments. While these platforms have demonstrated the power of AI in drug discovery,
      they present significant barriers for the thousands of biotech companies whose proprietary biological data, trade secrets, and
      regulatory-sensitive information represent their most valuable assets.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KALA&rsquo;s
      on-premises, data-sovereign model is designed to address this gap directly. The Company believes the competitive moat of the Researgency
      platform is built on several key advantages:</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exclusive
            License:</B> KALA holds exclusive worldwide rights to the Researgency platform within the biotechnology field.</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Data
            Never Leaves the Client:</B> Unlike centralized models, the Researgency platform deploys within the client&rsquo;s own environment.
            This eliminates a large barrier to AI adoption among data-sensitive biotech companies.</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deep
            Customization:</B> Each deployment features purpose-built AI agents tailored to the client&rsquo;s specific datasets and
            therapeutic areas, creating high switching costs and long-term client retention.</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform
            Network Effects:</B> As KALA deploys across multiple clients, the Company&rsquo;s understanding of biomedical AI agent design,
            RAG pipeline optimization, and deployment best practices should increase &mdash; creating an operational expertise moat that
            is expected to grow with each new deployment.</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
      KALA Intends to Use Researgency Internally</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
      its own first deployment client, KALA intends to apply AI-driven analytical tools through the Researgency platform to:</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reassess
            historical preclinical and clinical datasets</B> &mdash; including the substantial biological data generated by the Company&rsquo;s
            MSC-S platform across growth factors, protease inhibitors, matrix proteins, and neurotrophic factors</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identify
            additional therapeutic indications or development pathways</B> &mdash; by using AI to detect patterns in complex, multi-factorial
            biological data that conventional research methods may have overlooked</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Optimize
            trial design and probability-of-success modeling</B> &mdash; reducing the time and cost associated with future clinical programs</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Support
            regulatory and commercialization strategy evaluation</B> &mdash; including analysis of the Company&rsquo;s existing FDA Orphan
            Drug and Fast Track designations for its KPI-012 product candidate</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
       <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: right"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Automate
            literature review and competitive intelligence</B> &mdash; enabling the Company to continuously monitor developments across
            the rapidly evolving AI-biology landscape</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      Company expects to report preliminary findings from its internal AI-driven data reassessment during the 12-month initial term,
      providing investors with tangible evidence of the platform&rsquo;s capabilities prior to external deployment.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
      Agreement and Terms</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
      the Agreement, KALA has secured exclusive worldwide license rights to the Researgency platform within the biotechnology field (as
      defined in the Agreement) and has received initial platform access to evaluate and demonstrate its capabilities. The exclusivity
      applies to the custom, dedicated platform configured for KALA and does not restrict Younet from operating its standard, generally
      available, multi-tenant SaaS platform. The Company intends to assess the platform&rsquo;s performance during the 12-month initial
      term and, subject to satisfactory results, may elect to extend the Agreement for successive 12-month renewal terms, which would
      include expanded deployment of custom biotechnology-focused AI agents, RAG pipeline optimization, and full-scale integration with
      the Company&rsquo;s proprietary data systems.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      Agreement will be filed as an exhibit to the Company&rsquo;s Current Report on Form 8-K with the Securities and Exchange Commission.
      Investors are encouraged to review the full text of the Agreement for complete terms and conditions.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Management
      Commentary</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
      opportunity we see is simple but enormous,&rdquo; said Avi Minkowitz, Chief Executive Officer of KALA BIO. &ldquo;The biotech industry
      is generating more biological data than ever before, and the companies that can analyze that data fastest, find the patterns others
      miss, and translate those insights into therapies will help define the next era of medicine. But here is the problem: building
      AI infrastructure is expensive, complex, and requires specialized talent that most biotechs don&rsquo;t have. And the existing
      options ask biotech companies to hand their most sensitive data to someone else&rsquo;s cloud. We are building a third path, we
      expect to bring the AI to biotech companies, it will run on biotech companies&rsquo; servers, the data will stay with the biotech
      companies, and they will get the analytical information that the largest pharmaceutical companies obtain internally. That is the
      future we are investing in.&rdquo;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.&nbsp;Minkowitz
      continued: &ldquo;We are starting with ourselves. KALA is client number one. We will prove this platform on our own data, our MSC-S
      platform, our KPI-012 program, our IP portfolio. And once we have demonstrated what it can do, we intend to make it available to
      the broader biotech industry. We believe the companies that win in the next decade will not be the ones with the most data, they
      will be the ones with the best AI infrastructure to extract value from that data. KALA intends to be a company that provides that
      infrastructure.&rdquo;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capital
      and Corporate Matters</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      Company maintains an effective registration statement with the U.S. Securities and Exchange Commission, providing flexibility to
      access public capital, subject to market conditions and regulatory compliance. The Company may also attempt to raise capital privately.
      However, there is no assurance that the Company will be able to raise capital on favorable or acceptable terms.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
      KALA BIO, Inc.</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KALA
      BIO, Inc. (NASDAQ: KALA) is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform
      for the biotechnology industry. The Company&rsquo;s dual strategy combines a proprietary biologics pipeline, including its mesenchymal
      stem cell secretome (MSC-S) platform and FDA Orphan Drug and Fast Track designated product candidates, with a scalable AI platform-as-a-service
      business designed to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments. Through
      its exclusive license for the Researgency AI research platform, KALA intends to serve as the dedicated AI infrastructure partner
      for the biotechnology industry, enabling companies of all sizes to unlock the value of their proprietary biological data without
      ever surrendering control of it. For more information, visit www.kalarx.com.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
      Statements</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
      press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including
      statements regarding the Company&rsquo;s strategic initiative to build an AI infrastructure platform for the biotechnology industry,
      plans to develop and deploy the Researgency AI platform both internally and to external clients, expectations regarding the potential
      benefits of AI-driven analytical tools, plans to reassess historical datasets and identify new therapeutic indications, expectations
      regarding the AI drug discovery market and industry trends, expectations regarding the Company&rsquo;s ability to generate recurring
      platform revenue, plans regarding potential partnerships, client deployments, or technology licensing opportunities, expectations
      regarding the Company&rsquo;s competitive position and the differentiation of its on-premises deployment model, the potential exercise
      of development continuation or renewal options under the Agreement, and other statements that are not historical facts.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      Company used words like &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo;
      &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
      &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo;
      and similar expressions to identify these forward-looking statements. These statements involve known and unknown risks, uncertainties,
      and other factors which may cause actual results, performance, or achievements to be materially different from those expressed
      or implied by such statements. Important factors that could cause such differences include, but are not limited to: risks that
      AI technologies may not produce expected results in drug discovery or development; risks related to the development, deployment,
      and performance of the Researgency platform; risks that the Company may not successfully attract or retain external platform clients;
      risks that the platform-as-a-service business model may not generate anticipated revenues; risks that the Company&rsquo;s product
      candidates may not be successfully developed or commercialized; risks related to the Company&rsquo;s limited cash resources and
      ability to continue as a going concern; risks that the third-party information contained herein was not accurate at the time it
      was published and/or does not accurately predict the future; risks related to the Company&rsquo;s ability to raise future capital
      and the possibility that market conditions may limit the Company&rsquo;s ability to raise capital on favorable terms; risks related
      to the Company&rsquo;s ability to regain compliance with Nasdaq listing requirements; competition from larger, better-resourced
      companies including major technology and pharmaceutical companies; dependence on key personnel and third-party technology providers;
      the accuracy of third-party market forecasts and projections cited herein; risks that the Company may elect not to expand or continue
      its deployment of the Researgency platform beyond the initial term; risks that Younet may not perform its obligations under the
      Agreement; and other risks detailed in the &ldquo;Risk Factors&rdquo; section of the Company&rsquo;s Annual Report on Form 10-K
      as they may be revised in the Company&rsquo;s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and other filings
      with the Securities and Exchange Commission.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
      statements speak only as of the date of this release, and the Company undertakes no obligation to publicly update or revise any
      forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.</FONT></P>
      <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact:</B></FONT></P>
      <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avi
Minkowitz</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AM@kalarx.com</FONT></P>
      <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->


   </BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>kala-20260303.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +KIpo7xRiXgen8uAZHZcOaaIKbPtxZ97SekhsmR/bRlajyUqXyuBnyP0h4m2YZgO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:kala="http://kala/20260303" elementFormDefault="qualified" targetNamespace="http://kala/20260303">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://kala/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="kala-20260303_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="kala-20260303_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>kala-20260303_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>kala-20260303_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="kala-20260303.xsd#Cover" roleURI="http://kala/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://kala/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 03, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  03,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KALA BIO, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001479419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0604595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1167 Massachusetts Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">996-5252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KALA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="kalabio_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kala/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>kala-20260303.xsd</File>
    <File>kala-20260303_lab.xml</File>
    <File>kala-20260303_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="kalabio_8k.htm">kalabio_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "kalabio_8k.htm": {
   "nsprefix": "kala",
   "nsuri": "http://kala/20260303",
   "dts": {
    "schema": {
     "local": [
      "kala-20260303.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "kala-20260303_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kala-20260303_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "kalabio_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://kala/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kalabio_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kalabio_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://kala/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001829126-26-001911-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001829126-26-001911-xbrl.zip
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MQ&R?1EBDV,UAMS'_Q^]V$1:?78+Y[1\:]H N* =?UP(-F*GIY6]02P,$%
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MS-)$#6"]D+2ESD\W +.M4P]#%Q0G@#GXE*32^R5E\4@H5;<#,.L?4&QBU[3
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M(&8Z#4+O<)<Y/PYKXR+*TRN6&5&_%Y&\D"\XPZ4WL+V0W/5+E5VFS;<I;=J
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M>&5L,6@LC&N*(!@!;4'+XOIO!?C)G;==T22ZHAS#5UD:&L<9\]KVC&1Y!T%
M!+1=02GR<B'*E5[Z_S-F3V+[G$7[.\$C0M135FDU6O5=?QL8[9:9-S6I2=.@
MT( X>XM?@,!#%:A6QX?:C.7S8IYZ:%QE<^/1T^(1RP-XN\U2-8-*8_!5\,X@
MQ[<7!C3 N,G0$1$0>@-L0C<<\DB4AWY 13"J17LZ/TL/60!)_'E_3QZ(4.\=
M+,DN^RQW]-1QAC$@UO79V^#FF"=SO8%!0/A6M]"I7HKJ%:"5>D:LK +]IBI!
M>2VVWR^O;[J6G^1FO4G^M<(ID5O^"U!+ P04    "  92F1<],U3/U0'  #$
M5P  %0   &MA;&$M,C R-C S,#-?<')E+GAM;,V<RW+;-A2&]YWI.[#J6O?$
MK16[&5NQ,IHXL6LY2=M-!B(A"6,0T "D);U] 5)4="' XPV/O;!EZL?E_P""
M/ 3 B_?KF ?/5&DFQ66CV^HT BI"&3$QOVQ\G32O)L/QN!'HA(B(<"GH94/(
MQON_?OTE,#\7OS6;P8A1'@V"#S)LCL5,O@N^D)@.@H]44$42J=X%WPA/[1$Y
M8IRJ8"CC):<)-5_D!0^"L]8;$C2;@&R_41%)]?5AO,MVD21+/6BW5ZM52\AG
MLI+J2;="&<,RG"0D2?4NM\ZZL_W)DU]P)IX&]M>4:!H87$(/UII=-FRYVV)7
M_994\W:OT^FV__E\.PD7-"9-)BRVD#:*5#:7LG3=\_/S=O9M(3U1KJ>*%V7T
MVT5U=CF;;YE'OU<3S08ZJ]ZM#$F2M7IE,8%38?]K%K*F/=3L]IK];FNMHT8!
M/R.H)*</=!9D-@?)9FEZDF:V(S2VQQ:*SBX;3X03DU'OK-/O]&TVOP^EZ9^-
MP&9@FGU772MLVX/MK:!]4-Y244U%DEF\-0<."J;KQ'0C&A5%VVS<&6]3LL2*
MMIVC&S1M3TIC4X;YF"NW%2BJP&5X4"JWQ*4Z]%OTWHRKIF%K+I_;$66&;^^M
M_6!AO,U F']^9 5=376B2)@4.7$RI3S+_X?1'$G:-=2J(/%H<BROU*'BN$[[
MC76EPD"JB"K#NLB+J/"@B4X[XE;17A)E,FJ&"\9WK3M3,G;1V9*0CHKN@S)%
MU$/SRI0?V3J,.)F7XSR2 'EV,8"6NL$B^H'J4+&EY5(!]D )Y-M#Y5OBK6;,
MQ;GS0.?,UM=6Q5Y>J3WH'Q<<28#@^Y@CA=<M4@M<"9$2_D"74E6 /U0">;_!
MY%WF#0GSWRE1"55\ R%](@;"?HL)V^$0B?>C(D(SRP<"_%0-)'Z&>N/A\(B$
M?+*@G-N(C0A0+R_3 ['_@8G=[?,5@+]YMM=W<VF!L]]+ L3_YVO!?^(6J07N
MJ6(R,I=T!6!_(@92/\>D[G"(ROM&1%#:.RDX_L&'?60/"?6(Z9#PO$8C<TS[
M<9?(H<A18LY*FZC8_Z5$@:'OB:'(4<+0"HLU Q^F2AU4QCNJN-50Y"@!:)7)
MFIG?B(0E&_N(_TL:3W\^.#UD?:J",D8).EVF4-@63QI$8J<N?'R/E5#&*+&F
MSQP*YZ'QHP@?BXBN/]&-#_2)%$H:)<;TVD-!?:]83-1FPL+J0>-4"X6-$EGZ
M#:+0?B3K<61<L1G+)_^JH3N30-FCA)4@NRA-,!:A5$NY][AX*%-S/FZ&,O(.
MZ14)H<V!$F^^P#I*HUQ%D<&EMW]NF:!=7U.4RL%S1'@-X+'Y2K#W7H:]!\>.
M$H=6VGPEV/LOP]Z'8T>)12MM8F(?FH]WZE&N'#/03C$4.4HL6F$1$WAVI;E3
M]TH^LWP-5!7UDQ10](@AJM\L:H?/+_*0WEXHH;P1P]5R<YB<[Z5."/^/+:ON
M),OU4.:(@:O/:-T/&/-VMP\M7$N)CB10OBBQ:JF=NI':%E:4N+OOH0(*%"4
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M,MA[/SX]&.\'RT24TRQ?$);GX$.6'!%(0G4P W1:N*VKD#X"%[JL\J+"\X@
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M*%F; ?SCE?60"_#8#Y:Y7 !^PJ'PH <% JZ$MP+OK4JGN0!WN +/.9=TGD\
MN"G<^0=]3#PX/.X-[JXHE(=J#]6[ M5G?89J[7BB$X8!?2(1!T4PE;!)"<,
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MC?FA-A6.\.B/=Q('/>P=GVBMKG9ZTAT(E]OA;9TRN6T%7J=X>44G;&KPKL\
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M=(:+N!K\1H# AS"7]Q0O[_3\PWCTRQ#O"1[D[6!T';P?7/\\O E^&9Q_L'^
M)5_CK;N@G\YP:?"7T7C\87!Q.D1&[KW7%[SA2X'3XJ,87/P&7S@;7<,=PUMS
M2@]@<!["^B_&P__]P(\#7HRKX2G]X^K#Q>@&%DJW?OBOX?NK\\'U;["0]X-W
MPW$8X.VZ/CL?CL?V4BZOW].CIH>"7X/?7L)WX'?VKNZ,5]*3#&TC07MY\>X2
M#% P_G!U=7E]0Z*@[P>XY2[PI?()6V]V>VIVCX]ZG[$=I8HFD5!GY[A:8M_(
MMD;783N[AUGGU[9HM$[P7 M:%7SN35P;<X)FFO+7+/]((TO<H<V#"&6O]L.@
M#M=%@;WHM8Z5H(^$P404*@K*/*OP>/,LJ[5(LUR9"/PP@'@GEC$F.V3<H/U8
M[2V,AFTS"B9*15'F$ \CK;E6Y!+TDVZTR6QS2]Q](X.)7&4TLU)0 TQ#S\NR
MQ-T ?F?LG(=8#[$68GN>,+V6J;S[8Q!+V4'W. ]B;);.,IKUVX0BC;(A-BTP
M8CJ-'EJ%WT*R@YJBH$*.21B:I;AH?!@@TZJ(LB6W3R0(D]14HI$=V91K%U(W
MYHFU.3+2E?\?(KF*1@]<\!PLU!@H6&[Z3A62U0=BIU_2@Z$'P]T#PY[G>09Q
MK$I6#AI@L08@Q'I3CQE'A5KT.)L$&YD7)&V?: $2.R"OR<X6]8DCN+)L$0Q&
MIEX$4&+Q4*9S1#R>RJ(=,-<Q0VCK@K^P/>C%JL%S-=P./N>A+G9N'DUSH46R
M$./*>(*$I&%0PBU-5*K!V;T*'$.8%IPSFYI.;Y1B\L#G@6_W@*_G,_=N<G"T
MV"MY/!G*^'>,7!@!HD,& &(^9335<#H2G69C3*F+V.PIX5\_+*=YAGVV8H4P
MM._,5,HQ% =7JJ(CM8Z\[LJM';KVV=Y*20$Y?RL26'OFSV 9FI%M 8<'3]46
M 78RL.U+ K<QUNEF>/V>TK;XC]&%Y]EZ:])K:W+<^[0MXNWV[G)C>) 9 <TZ
M/0:&A].I%NLY0_T#HUC3,!V=LM\<]K</+RJT4W1G:,K34N7(E&+'.(T-O#<.
M7Z66TVODR[&_:CWR)W$&%#[:F")XRV$ -63%6KO<-56'P7!S(J)#VEQABYBV
M3/48[4+!\Q-YXP*1J09&DS0UB*)57Q.1T?Z$*Z,[GDO*"&=!@H5S\Q33:C'!
ML *3+I3BQ@?J7N7NS':ZCY]U[/E9Q,\Z]OPL[W%XC^/+\#AZ7L48UE/;L<"0
M565ME;;U1$93;=TSR6+#9O90ERU<Y@J=$)-,JV?&=[@.:.#35:M"4G;Y/<92
M-_R3IF-">;22O 1J$:6?ZP4P?=O5'Y9@A".DB&M&]L#H#NMSFA'WDLG9C<B>
MAC^"&3>B,@Z]VQ&HZ$HX!I3RH]+*:\O3UD?-)96&L[L4/(VY6E(*$GZ/]7)L
MUD&F=CTBAN-OFMDBX_J^UY=<#Z)LK%V?1;N3=3+2SGWN.-0AO'6*KI2GB3IW
M 9^@X>"OFN-$IYJ8;FGH,M$$@91G5[.GMS/.C3<<WG!8P]'SBL^-1C]3IC@5
M52&WYO6Z6(&U'HNE;7BOEMFZ-*YIR6$@,B68E V,FCH(8\Y@%5BY)0<Y.P!+
MA,.%M3Z-$R,T3H5*6.J7B^Q@,'1+CRM(ZZSN %9GUL&JL!Z[/';M'G;UO6C3
MPJY1"K'_+031VS<F; U@:L&2HA+ A\#L0;AB3W0BP?F2F*/BM>D6P*E"'Q%'
M]I54,<8<UD2D'_-J648XBYW4CPB7G _AMV)W3GAIN(?HK:MBH8H"/F!037U"
M/'NNT=9V#"[$1P).8A#-4KH\DU&<@"L[55229PWM+-^=I)3'/H]]%ON>]1O[
MN") 6@X.#&Z+>Q0YEPY\(OFO%<2[\,=8AK&@CJ4+'O1#'=,F[-3L<23*4-17
M:S9R&.E":"OHWG1DEY5NCZM/]T9$'V<Y_#L.1E<FYU_EMQCQ=PY'EBJG\Q8<
MD*]%W!@E)Q+/+ H[5@%- ?[;N5>V%%&'Z#A] -,3$-';V1 AGU?/4BB6.'$-
MJP53G0ZQ3,ZP10.E1O*%FNF'0;WNB-59I(CA3H<ETZ 7L'I-T;].;!384];4
MO+.">K>2%?58,@N[['0RY%FP-XA^K\"+IG->+O%_X._/W;9Z/72A")X='CVG
M"X9_O(!/O0B#[\/@)9.@CD]:#Z-LO)^[84IZ0Q1H, 7>#2^&U]Q#^<MHC%V2
MGB?@C7A?C?A)[WD"J-.RE/ ?P.A3^'LN4$+ED1PT1;Z\<@X5V4-I'41,@U@Q
MEI!YM2&U#- P4/C<OS,%7\3X! P0E:C1;F%K%882,Z:,=23L)Y)&B8+I8K,)
M08.@:4CU"?.#^LSZE)CT7C\MB["@@<&<^$26=U*/.M)TXIVQ'A[#/(99#.MY
MY7%@DPC;XE:SQ(19%TY$M!%&^\F 14C;,=IU>6/B*%)MN*QGRIXTR:N14$:
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MIHP4S60. Y4D<H;,=L"2*I7I-,LCB1EL'N2<8^:(:NEUQ=EVK>.?$)MPG'-
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MJ7MUN4Q,-ZF>HFAK%:Z1?S\^/1C76I&U5_'SU>C@Z/@$/BS!$4BM&V)_8+^
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MG-BD;HO[9'AM_#SG7RZGD_'Y;U!+ P04    "  92F1<WO#NS>@L  #8$P$
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M0XE!:)1W "]LX>LF /9,]QT1Z*.+*[O:L+3AVF+ W<&8Z?$],(Q<X@[>?B@
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M@_7HAGSQ-K9Q;:K\5K+(]W)<,3X/&8(L+K3BIC$.JE ;/.L^J-5M]8_-2#A
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M[G-[BI6WROV1[U#KHNV[=!4OW B$5_NA]%52YNF26K)6KI*N86&$%1%J983
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M,#(V,#,P,U]P<F4N>&UL4$L! A0#%     @ &4ID7*WL16T9&@  [)\   X
M             ( !!Q8  &MA;&%B:6]?.&LN:'1M4$L! A0#%     @ &4ID
M7!?2>VQ/<0  B&($ !(              ( !3#   &MA;&%B:6]?97@Q,"TQ
M+FAT;5!+ 0(4 Q0    ( !E*9%S>\.[-Z"P  -@3 0 2              "
M <NA  !K86QA8FEO7V5X.3DM,2YH=&U02P4&      8 !@"! 0  X\X

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>kalabio_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kala-20260303.xsd" xlink:type="simple"/>
    <context id="AsOf2026-03-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479419</identifier>
        </entity>
        <period>
            <startDate>2026-03-03</startDate>
            <endDate>2026-03-03</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-03-03" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-03-03" id="Fact000004">0001479419</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-03-03" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-03-03" id="Fact000010">2026-03-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-03-03" id="Fact000011">KALA BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-03-03" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-03-03" id="Fact000013">001-38150</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-03-03" id="Fact000014">27-0604595</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-03-03" id="Fact000015">1167 Massachusetts Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-03-03" id="Fact000016">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-03-03" id="Fact000017">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-03-03" id="Fact000018">02476</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-03-03" id="Fact000019">(781)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-03-03" id="Fact000020">996-5252</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-03-03" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-03-03" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-03-03" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-03-03" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-03-03" id="Fact000025">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-03-03" id="Fact000026">KALA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-03-03" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-03-03" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
